| COMPANY | DATE | MAJOR EVENT | TYPE | CLOCK |
|---|
AbAg | 2003 .10 | Round-financing : undisclosed M€, by OTC Innovation | RFIN | [3 years] |
| Abcys | 1999 .12 | Company founded by Jean-Pierre Mouscadet and Thierry Martin | ORGF | [0 year] |
| AB Science | 2010 .05 | Listing on Euronext Paris : 31.6 M€ (55.0 M€ expected) | PBO | [8 years] |
| AB Science | 2008 .09 | Registration : positive opinion from EMEA for lead compound masitinib in the treatment of canine mast cell tumor | MKTG | [7 years] |
| AB Science | 2007 .05 | Court : legal prosecution against Medicen, Paris Pôle de Compétitivité, with a claim of 125 M€ | LEGAL | [5 years] |
| AB Science | 2001 .07 | Company founded by Alain Moussy | ORGF | [0 year] |
| Adocia | 2010 .01 | 2nd round-financing : 14.0 M€, by InnoBio (for 6 M€), SHAM (for 2 M€), and previous shareholders, including the founders | RFINB | [4 years] |
| Adocia | 2008 .04 | 1st round-financing : 12.0 M€, by AGF P.E., Société Générale A.M., Bioam Gestion, Vivéris Management | RFINA | [2 years] |
| Adocia | 2007 .00 | Financing (no interest loan) : 2.25 M€, by OSEO, for its osteoporosis project | DEBT | [1 year] |
| Adocia | 2005 .12 | Company founded by Gérard Soula (ex-Flamel Technologies, CEO, during 15 years), and his 2 sons, Olivier (born 1970) and Rémy, initially named PPM (Proteins & Peptides Management), investing 1.6 M€ | ORGF | [0 year] |
| Advicenne Pharma | 2007 .04 | Company founded by Luc-André Granier | ORGF | [0 year] |
| Affichem | 2007 .01 | Partnering research agreement with SAFC to provide chemical development services for Dendrogenine A, a potential cancer treatment | R&D | [4 years] |
| Affichem | 2002 .10 | Company founded by 2 Inserm researchers, Marc and Sandrine Poirot, and by Philippe Rivière and Stéphane Silvente | ORGF | [0 year] |
| Agate Bioservices | 2005 .04 | Company founded by Hassan Chaabihi, within École des Mines d'Alès (EMA engineers' school) | ORGF | [0 year] |
| Aisa Therapeutics | 2007 .10 | Seed financing : undisclosed M€, by 2 business angels | SFIN | [2 years] |
| Aisa Therapeutics | 2005 .10 | Company founded by Patrizia d'Alesso (Inserm), with Aisa meaning Anti Inflammatory Senescence Actives | ORGF | [0 year] |
| Alfact Innovation | 2006 .01 | Company founded by Gilles Amouyal and Paul Amouyal (chairman, born 1955, M.D.), with Marc Le Bozec as COO (up to October 2006), from technological tools exclusively licensed from Inserm | ORGF | [0 year] |
| AliX | 2008 .12 | Partnering R&D agreement with Sosho, an Osaka university spin-off, for protein structure determination of intractable targets | R&D | [6 years] |
| AliX | 2008 .10 | Acquisition of Novalix (by merger and integration), a contract research biotech company (60 employees) specialised in protein production and cristallography analysis | ACQ+ | [5 years] |
| AliX | 2008 .09 | Nomination : Denis Zeyer, new CEO, replacing Jean-Paul Renaud, back to academic activities | ORGN | [5 years] |
| AliX | 2002 .11 | Company founded by Jean-Paul Renaud, Jean Cavarelli, Dino Moras, Olivier Poch, Marc Ruff, Jean-Claude Thierry, Jean-Marie Wurtz, and Marat Yusupov, as a spin-off from the Department of Structural Biology and Genomics (DBGS) of the Institute of Genetics and Molecular and Cellular Biology (IGBMC) | ORGF | [0 year] |
| Alizé Pharma | 2010 .01 | Partnering R&D agreement with Eli Lilly (USA) on unacylated ghrelin (AZP-01) program for the treatment of type II diabetes (with licence option) | R&D | [2 years] |
| Alizé Pharma | 2009 .09 | 1st round-financing : 3.0 M€, by SHAM and previous investors | RFINA | [2 years] |
| Alizé Pharma | 2008 .05 | Licensing-in of preclinical recombinant L-asparaginase program for the treatment of acute lymphoblastic leukaemia, a lead compound from EUSA Pharma (USA) | LICIN | [1 year] |
| Alizé Pharma | 2007 .09 | Seed financing : 0.7 M€, by 2 private companies, Octalfa (Gilles Alberici), CEMA (Canada, André de Villers) | SFIN | [0 year] |
| Alizé Pharma | 2007 .04 | Company founded by Thierry Abribat and André de Villers [co-financer, M.D., ex-Theratechnologies] | ORGF | [0 year] |
| Alphelys | 2009 .12 | Partnering distribution agreement with Biogen (USA) for Brazil market (exclusive distributor) | MKTG | [8 years] |
| Alphelys | 2008 .05 | Partnering distribution agreement with Zytomed Systems (Germany) for immunohistochemical reagents in France | MKTG | [6 years] |
| Alphelys | 2006 .10 | Partnering distribution agreement with Seroa (Monaco) for product portfolio in many countries worldwide | MKTG | [5 years] |
| Alphelys | 2005 .06 | Seed financing : 0.24 M€, by owners, as a capital increase from 0.16 M€ to 0.40 M€ | SFIN | [3 years] |
| Alphelys | 2002 .02 | Company name change from Amelys to Alphelys, due to pre-occupied name | INFO | [0 year] |
| Alphelys | 2001 .10 | Company founded by Pierre Chaumat and Pierre Defrenaix (initially named Amelys) | ORGF | [0 year] |
| Ambiotis | 2009 .03 | Company website completed and revamped in 2 languages | INFO | [1 year] |
| Ambiotis | 2007 .03 | Company founded by Marc Dubourdeau (initially named as 2iPharma) | ORGF | [0 year] |
| Anaconda Pharma | 2008 .05 | Company move from Paris Pasteur Biotop incubator to Paris Biopark with new R&D facilities | ORGL | [4 years] |
| Anaconda Pharma | 2007 .01 | Round-financing : 2.6 M€, by private investors | RFIN | [3 years] |
| Anaconda Pharma | 2006 .10 | Financing : leader company in the CristaLead Program, with a minimum of € 1 Million grant | RFIN | [3 years] |
| Anaconda Pharma | 2003 .10 | Company founded by Dr Moshe Yaniv and Dr Françoise Thierry (both from Institut Pasteur), Dr Michael Botchan (Berkeley), and Marta Blumenfeld and Jean-Michel Gauthier, as a spin-off from Institut Pasteur | ORGF | [0 year] |
| Aptys Pharmaceuticals | 2008 .12 | Seed financing : 0.5 M€, led by Sofimac Partners, with contribution of CACF Développement (Crédit Agricole Centre France) | SFIN | [6 years] |
| Aptys Pharmaceuticals | 2007 .05 | Clinical trial (phase III) for a new formulation product based on the Bi-Gel technology in the USA (beginning) | CLIN | [4 years] |
| Aptys Pharmaceuticals | 2004 .02 | Launch of new trade mark as «The Formulation Company» | MKTG | [1 year] |
| Aptys Pharmaceuticals | 2002 .11 | Company founded by François Boutignon, Jean-Marc Aiache [Pharm.D., Ph.D., Professor Emeritus], and Michel G. Lepers [Professor of Technology transfer at University of Auvergne, founder-CEO Eurobiobiz], as a spin-off of the University of Auvergne | ORGF | [0 year] |
| Ariana Pharmaceuticals | 2010 .02 | R&D partnering with Fovea on Phase II clinical data analysis, with KEM clinicals, a new version of its decision support platform KEM (undisclosed fees) | MKTG | [6 years] |
| Ariana Pharmaceuticals | 2009 .08 | Financing (no interest loan) : 10.0 M€, by OSEO Innovation, for oncology biomarker program IMAkinib (with Oncodesign and Guerbet) [Ariana part : 1.0 M€] | DEBT | [6 years] |
| Ariana Pharmaceuticals | 2008 .07 | Round-financing : 1.5 M€, by Vizille Capital Innovation (Crédit Mutuel - CIC) | RFIN | [4 years] |
| Ariana Pharmaceuticals | 2008 .03 | Launch of new KEM multi-objective data analysis and decision support | MKTG | [4 years] |
| Ariana Pharmaceuticals | 2005 .12 | Licensing-out of KM platform to Institut Pasteur, against a minority share | LICOUT | [2 years] |
| Ariana Pharmaceuticals | 2003 .08 | Company founded by Mohamma Afshar and others, as a spin-off from Institut Pasteur | ORGF | [0 year] |
| Aterovax | 2010 .04 | Partnering distribution agreement for sPLA2 Activity Test in Europe with SPI-BIO (research use, only) | MKTG | [3 years] |
| Aterovax | 2009 .11 | Research : publication in European Heart Journal of Clinical trial evaluating systemic sPLA2 association with prognosis in patients with coronary heart disease (1024 patients with CHD) | R&D | [3 years] |
| Aterovax | 2009 .11 | Clinical trial (phase III) for sPLA2 activity, as a stronger marker for risk prediction (ending) | CLIN | [3 years] |
| Aterovax | 2008 .07 | Financing : grant of 1.45 M€, by ANR, for the cardiovascular therapy program | RFIN | [2 years] |
| Aterovax | 2008 .06 | Prize : Siemens Innovation Price 2008 (Health) | MKTG | [2 years] |
| Aterovax | 2006 .07 | Seed financing : 3.0 M€ by SGAM (Specialized European Fund for Therapeutic Innovation) | SFIN | [0 year] |
| Aterovax | 2006 .06 | Company founded by Alain Tedgui, Ziad Mallat, and others, from Inserm exclusive worldwide rights to 3 filed patents covering current biomarker products and the immunotherapy program | ORGF | [0 year] |
| Atlantic Bone Screen | 2008 .05 | Acquisition of Atlanchim, molecular chemical synthesis subcontractor (at book value, plus 5 maintained jobs) | ACQ+ | [2 years] |
| Atlantic Bone Screen | 2005 .11 | Company founded by Ronan Le Bot, Dr Dominique Heymann, Dr Françoise Redini, Dr Marc Padrines, Dr Yannick Fortun, and Prof. François Gouin | ORGF | [0 year] |
| Aureus Pharma | 2010 .03 | R&D partnering in Biointelligence R&D programme of € 118 Millions, designed to promote the use of systemic modeling and simulation tools to exploit biomedical databases and coordinated by Dassault Systèmes (with notably Sanofi-Aventis, Ipsen, Servier, Pierre Fabre, Bayer) | R&D | [10 years] |
| Aureus Pharma | 2010 .02 | Licensing-out of DDI Project 2009 to Sanofi-Aventis | LICOUT | [10 years] |
| Aureus Pharma | 2008 .08 | Launch of new software solution AurPROFILER (to rapidly evaluate target, cell and drug profiles using bio-assays) | MKTG | [8 years] |
| Aureus Pharma | 2007 .11 | Licensing-out of Aurscope GPCR to BMS (renewal) | LICOUT | [7 years] |
| Aureus Pharma | 2002 .11 | Licensing-out to Servier and Aventis | LICOUT | [2 years] |
| Aureus Pharma | 2006 .12 | Nomination : Jason Theodosiou, new CEO, André Michel, founder, moved to supervisory board | ORGN | [6 years] |
| Aureus Pharma | 2004 .10 | 1st round-financing : 3.0 M€, by OTC A.M., AXA P.E., and previous shareholders | RFINA | [4 years] |
| Aureus Pharma | 2002 .01 | Company (holding of Aureus as an SCP) founded by Dr André Michel | ORGF | [2 years] |
| Aureus Pharma | 2000 .09 | Seed financing : 0.8 M€, by Bioam | SFIN | [0 year] |
| Aureus Pharma | 2000 .01 | Company founded by Dr André Michel [born 1944, CEO, Ph.D. chemistry, Namur, ex-Servier, Neokimia] | ORGF | [0 year] |
| BCell Design | 2008 .03 | Seed financing : 0.1 M€, by Limousin Participation, Limousin Expansion, Limousin Business Angels | SFIN | [0 year] |
| B Cell Design | 2008 .01 | Company founded by Michel Cogné (SAB), Armelle Cuvillier, based on a patent from Limoges University | ORGF | [0 year] |
| BioAlliance Pharma | 2010 .04 | Registration : positive US FDA approval for Oravig (Loramyc in EU) with US$ 20 Million milestone payment from Strativa Pharmaceuticals, the commercial partner in the US | MKTG | [13 years] |
| BioAlliance Pharma | 2010 .04 | Licensing-out of European commercialization rights for Loramyc and Setofilm to Therabel (Belgium) in a € 48.5 Million deal | LICOUT | [13 years] |
| BioAlliance Pharma | 2009 .12 | Clinical trial (phase II) for Clonidine Lauriad (beginning) in radiotherapy and chemotherapy-induced oral mucositis and clinical trial (phase I) for AMEP (beginning) in invasive melanoma | CLIN | [12 years] |
| BioAlliance Pharma | 2009 .10 | Clinical trial (phase I) for Fentanyl Lauriad, slow-release central analgesic in cancer patients (beginning) | CLIN | [12 years] |
| BioAlliance Pharma | 2009 .04 | Clinical trial planned, after first preclinical trial results on new oral Irinotecan nanoparticle formulation for the treatment of advanced colorectal cancer | CLIN | [12 years] |
| BioAlliance Pharma | 2009 .04 | Financing (no interest loan) : 6.3 M€, by OSEO Innovation, to support Cancer Anti-invasive Program (CAP) private-public consortium (with Oroxcell and Xentech) | DEBT | [12 years] |
| BioAlliance Pharma | 2009 .03 | Licensing-out of Loramyc rights to SpeBio (2007) in Europe regained (withdrawn contract and legal suite) | LICOUT | [12 years] |
| BioAlliance Pharma | 2009 .02 | Registration : submission to EMEA of ondansetron RapidFilm | MKTG | [11 years] |
| BioAlliance Pharma | 2008 .12 | Management restructuring : 9 heads employee reduction, i.e. 12% of total headcounts | ORGR | [11 years] |
| BioAlliance Pharma | 2008 .09 | Financing : capital investment by AGF Private Equity (over 5% of equity) | RFIN | [11 years] |
| BioAlliance Pharma | 2008 .08 | Nomination : Pierre Morgon as COO, along Gilles Avenard (Pierre Morgon resigns in May 2009) | ORGN | [11 years] |
| BioAlliance Pharma | 2008 .05 | Licensing-in of European rights of Ondansetron spray from NovaDel | LICIN | [11 years] |
| BioAlliance Pharma | 2008 .03 | Company (as Laboratory BioAlliance Pharma) founded by Dominique Costantini for Marketing and Trade | ORGF | [11 years] |
| BioAlliance Pharma | 2007 .09 | Launch of Loramyc on French market | MKTG | [10 years] |
| BioAlliance Pharma | 2007 .07 | 4th round-financing : 40.0 M€, led by Bryan, Garnier & Co, with international investors (private capital increase) | RFIND | [10 years] |
| BioAlliance Pharma | 2007 .03 | Licensing-out of Loramyc to PAR pharmaceuticals in USA, in a deal valued 95 MUS$ (15 MUS$ initially, plus milestones) | LICOUT | [10 years] |
| BioAlliance Pharma | 2006 .10 | Registration : obtained for Loramyc, in France | MKTG | [9 years] |
| BioAlliance Pharma | 2005 .12 | Public offering : 30.0 M€, Alternext, Eurolist | PBO | [8 years] |
| BioAlliance Pharma | 2004 .08 | 3rd round-financing : 2.0 M€ (follow-up), by Siparex Ventures | RFINC | [7 years] |
| BioAlliance Pharma | 2003 .05 | 3rd round-financing : 10.0 M€, led by Auriga Partners | RFINC | [6 years] |
| BioAlliance Pharma | 2000 .05 | 2nd round-financing : 7.0 M€, by Technolife, ABN-Amro, Spef, and previous shareholders | RFINB | [3 years] |
| BioAlliance Pharma | 1999 .09 | 1st round-financing : 1.5 M€, by 3i, Capricorn Venture, and a business angel | RFINA | [2 years] |
| BioAlliance Pharma | 1997 .03 | Company founded by Dominique Costantini and Gilles Avenard | ORGF | [0 year] |
| Biocortech | 2009 .09 | Patent : granted on new blood diagnostic test of depression (USA), relating to RNA edition of serotonine 5HT2c receptor | LEGAL | [7 years] |
| Biocortech | 2009 .04 | Clinical trial to validate the concept of a blood test to diagnose and monitor treatment of mood disorders and depression, in France (beginning) | CLIN | [7 years] |
| Biocortech | 2008 .03 | Patent : granted on small molecule antidepressant | LEGAL | [6 years] |
| Biocortech | 2006 .11 | Partnering research agreement with Servier on novel drugs to treat CNS disorders | R&D | [5 years] |
| Biocortech | 2001 .11 | Company founded by Dinah Weissmann and Jean-François Pujol | ORGF | [0 year] |
| BioCydex | 2008 .01 | Launch of Solvamax in London (UK) | MKTG | [5 years] |
| BioCydex | 2002 .12 | Company founded by Yves Cenatiempo and Mustapha Bengsir | ORGF | [0 year] |
| BioMedical Diagnostics | 2010 .03 | Partnering distribution agreement from Assuragen (USA) to commercialize its Signature Oncology Products in France | MKTG | [24 years] |
| BioMedical Diagnostics | 2009 .12 | 4th round-financing : 3.0 M€ by Truffle Venture and AGF P.E. | RFIND | [23 years] |
| BioMedical Diagnostics | 2008 .10 | Financing (no interest loan) : 5.4 M€ (and 2.5 M€ grant), OSEO Innovation, to support Tracker, a theranostics project concerning rheumatoid arthritis from Neovacs (leader) and Biomedical Diagnostics | DEBT | [22 years] |
| BioMedical Diagnostics | 2007 .00 | Nomination : Paul Magrez, as CEO (replacing Patrick G. Poty) | ORGN | [20 years] |
| BioMedical Diagnostics | 2005 .07 | 3rd round-financing : 5.0 M€, led by Truffle Venture and CDC Entreprise, with AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova | RFINC | [19 years] |
| BioMedical Diagnostics | 2004 .05 | Nomination : Patrick G. Poty, as CEO (Daniel Pierron on leave) | ORGN | [18 years] |
| BioMedical Diagnostics | 2003 .05 | 2nd round-financing : 9.4 M€, by undisclosed investors | RFINB | [17 years] |
| BioMedical Diagnostics | 2000 .05 | 1st round-financing : 4.6 M€, by undisclosed investors | RFINA | [14 years] |
| BioMedical Diagnostics | 1986 .00 | Company founded by 2 ex-Abbott managers | ORGF | [0 year] |
| Biométhodes | 2007 .12 | Patent : granted on Massive Mutagenesis | LEGAL | [10 years] |
| Biométhodes | 2007 .11 | Nomination : Gilles Amsallem as CEO [ex-Finance Director], taking over from founder | ORGN | [9 years] |
| Biométhodes | 2006 .02 | Partnering research agreement with Sanofi-Aventis to develop Solexis, a new technology | R&D | [8 years] |
| Biométhodes | 2004 .05 | Licensing-out of Massive Mutagenesis to Aventis Pharma for R&D optimization | LICOUT | [6 years] |
| Biométhodes | 2003 .10 | 2nd round-financing : 4.5 M€, by CDC Innovation, CIC Capital, FCJE (CDC) | RFINB | [5 years] |
| Biométhodes | 1997 .11 | Company founded by Marc Delcourt | ORGF | [0 year] |
| Biom'up | 2006 .07 | Certification : ISO9001, ISO13485 for design, development, production | INFO | [1 year] |
| Biom'up | 2005 .02 | Company founded by Sylvain Picot, Patricia Forest, Christian Gagnieu, as a spin-off from Laboratoire des Biomatériaux, University of Pharmacie (Lyon) | ORGF | [0 year] |
| BioProtein Technologies | 2010 .05 | 3rd round-financing : 0.52 M€, by existing investors | RFINC | [11 years] |
| BioProtein Technologies | 2009 .09 | Set-up of Transgenic Rabbit Models (TRM), a subsidiary servicing company dedicated to the development and supply of genetically modified rabbit models (www.transgenic-rabbit-models.com) | ORGC | [11 years] |
| BioProtein Technologies | 2006 .12 | Set-up of Bioprotein Transgenics, a subsidiary | ORGC | [8 years] |
| BioProtein Technologies | 2006 .03 | Company move from Paris to Jouy-en-Josas (IDF), within INRA premices, in order to join own existing laboratories | ORGL | [7 years] |
| BioProtein Technologies | 2006 .10 | Nomination : Jean Lignel as CEO (replacing CEO and founder, Marc Le Bozec) | ORGN | [8 years] |
| BioProtein Technologies | 2003 .04 | 2nd round-financing : 1.5 M€, by previous investors | RFINB | [4 years] |
| BioProtein Technologies | 2001 .05 | 1st round-financing : 8.0 M€, by Société Générale A.M., Gilde, Creagro, Iwic, Anvar | RFINA | [2 years] |
| BioProtein Technologies | 1998 .06 | Company founded by 3 INRA scientists involved in transgenic animal and cloning research, Louis-Marie Houdebine, Jean-Paul Renard and Bernard Jégou, and an experienced manager from the business consultancy world, Marc Le Bozec | ORGF | [0 year] |
| BioQuanta | 2010 .02 | Round-financing : 0.5 M€ (US$ 800 000) from private investors | RFIN | [7 years] |
| BioQuanta | 2006 .03 | Set-up of BioQuanta Diagnostics | ORGC | [3 years] |
| BioQuanta | 2003 .04 | Seed financing : undisclosed M€, by private investors | SFIN | [0 year] |
| BioQuanta | 2003 .02 | Company founded by Jean-Michel Mauclaire and others, in Aurora (USA) as BioQuanta Inc. and set-up of subsidiary in France (SaRL) | ORGF | [0 year] |
| BioSystems International | 2010 .02 | Partnering distribution agreement to Microbiochips for the commercialization of PlasmaScan antibody microarray products that speed-up identification of human plasma biomarkers | MKTG | [5 years] |
| BioSystems International | 2009 .06 | Licensing-out of BSI’s patented monoclonal antibody proteomics platform to Lohocla Research Corporation for the discovery of novel alcoholism liver disease biomarkers in blood | LICOUT | [4 years] |
| BioSystems International | 2008 .10 | 2nd round-financing : 3.5 M€ led by SGAM AI, with undisclosed private investors in order to foster R&D of lung, colon and breast cancer diagnostics to be marketed in 2010 | RFINB | [3 years] |
| BioSystems International | 2007 .03 | Nomination : Jean-Pierre Tirouflet as CEO, replacing co-founder | ORGN | [2 years] |
| BioSystems International | 2006 .03 | Partnering research agreement with AstraZeneca on arthrosis biomarkers | R&D | [1 year] |
| BioSystems International | 2005 .01 | 1st round-financing : 3.0 M€, by Société Générale A.M. | RFINA | [0 year] |
| BioSystems International | 2004 .05 | Company founded by Laszlo Takacs, Andras Guttman, Barry L. Karger, William S. Hancock, as a spin-off from Pfizer France R&D center of Fresnes (Parke Davis Jouveinal), with name shortened as BSI | ORGF | [0 year] |
| BMSystems (Bio-Modeling) | 2009 .06 | Launch of BioXplain, the first open platform for Iterative, Predictive and Integrative Biology, with BioXpr (Belgium) and Kayentis (electronic pen) | MKTG | [4 years] |
| BMSystems (Bio-Modeling) | 2008 .09 | Patent : application, with CEA life Sciences, covering new therapeutic strategies and a preclinical evaluation platform for psychiatric disorders | LEGAL | [4 years] |
| BMSystems (Bio-Modeling) | 2006 .12 | Spin-off of Pherecydes (keeping minority equity) | ACQ- | [2 years] |
| BMSystems (Bio-Modeling) | 2004 .08 | Company founded by Manuel Géa, François Iris, Gérard Dine, Paul-Henri Lampe, Pablo Santamaria | ORGF | [0 year] |
| Carmat | 2009 .10 | Production : inauguration of cleanroom facilities in Vélizy | INDUS | [1 year] |
| Carmat | 2009 .09 | Nomination : Marcello Conviti, new CEO, replacing Patrick Coulombier (COO) | ORGN | [1 year] |
| Carmat | 2009 .06 | Financing (no interest loan) : 33.0 M€, by OSEO Innovation, to support 5 year-development plans | DEBT | [1 year] |
| Carmat | 2009 .05 | Company move from Suresnes to Vélizy (both, near Paris) | ORGL | [0 year] |
| Carmat | 2008 .11 | 1st round-financing : 7.5 M€, by Truffle Capital, EADS, and Prof. Carpentier's foundation | RFINA | [0 year] |
| Carmat | 2008 .10 | Company founded by Alain Carpentier, with financial support by Oseo, based on a long collaboration between the renowned surgeon and EADS on implementation of biomaterials and cutting-edge technologies in the construction of an artificial heart | ORGF | [0 year] |
| Cellectis | 2010 .03 | Licensing-out of use of homologous recombination patents to Boehringer Ingelheim in order to obtain, breed and utilize animal models | LICOUT | [10 years] |
| Cellectis | 2010 .01 | Licensing-out of use of homologous recombination patents to Bayer HealthCare aimed to introduce new features into the genome | LICOUT | [10 years] |
| Cellectis | 2009 .10 | Public offering (2nd) on Euronext : 22.0 M€ (1.914 Million new shares at 11.50 € each) | PBO | [9 years] |
| Cellectis | 2009 .10 | Acquisition of Vectocell Technology from Diatos assets (bankrupt in May 2009), to accelerate therapeutic development programs | ACQ+ | [9 years] |
| Cellectis | 2009 .09 | Set-up of Ectycell, a subsidiary specialized in stem cells from adults | ORGC | [9 years] |
| Cellectis | 2009 .06 | Launch of cGPS Custom, new kits for targeted gene integration in native cell lines, by affiliate Cellectis BioResearch (later extended to human cell lines and in gene function studies) | MKTG | [9 years] |
| Cellectis | 2008 .12 | Launch of PI10.3, a new research kit for producing stable cell clones using gene targeting in just 4 weeks, by affiliate Cellectis BioResearch | MKTG | [8 years] |
| Cellectis | 2008 .11 | Research : publication in Nature Magazine on a Therapeutic Meganuclease to treat a severe skin inborn disease by the CNIO, the CRG and Cellectis | R&D | [8 years] |
| Cellectis | 2008 .09 | Financing agreement by AFM (French Muscular Dystrophy Association), 8.3 M€ granted over 5 years for research on 7 genes surgery of orphan diseases | RFIN | [8 years] |
| Cellectis | 2008 .06 | Court : legal dispute on patents against Shionogi | LEGAL | [8 years] |
| Cellectis | 2008 .05 | Set-up of 2 new subsidiaries in France, Cellectis Bioresearch and Cellectis Genome Surgery | ORGC | [8 years] |
| Cellectis | 2007 .02 | Listing on Euronext Paris : 21.2 M€ | PBO | [7 years] |
| Cellectis | 2005 .06 | 3rd round-financing : 5.6 M€, by BankInvest, AGF P.E., Odyssée, Edmond de Rothschild (follow-up) | RFINC | [5 years] |
| Cellectis | 2004 .04 | Company move from Paris (Institut Pasteur) to Biocitech in Romainville | ORGL | [4 years] |
| Cellectis | 2002 .05 | 2nd round-financing : 8.0 M€, by BankInvest, AGF PE, Odyssée, Edmond de Rothschild | RFINB | [2 years] |
| Cellectis | 2000 .11 | 1st round-financing : 3.8 M€, by Kaminvest | RFINA | [0 year] |
| Cellectis | 2000 .06 | Licensing-in of 6 lead products from Institut Pasteur (spin-off with equity) | LICIN | [0 year] |
| Cellectis | 2000 .01 | Company founded by André Choulika and David Sourdive | ORGF | [0 year] |
| Cellial Technologies | 2007 .12 | Nomination : Sandrine Leman [Institut Pasteur], as CEO, replacing Yves Wendzinski | ORGN | [6 years] |
| Cellial Technologies | 2002 .12 | Nomination : Yves Wendzinski [Eng. ISEN] as CEO (also Chairman), replacing Michel Major | ORGN | [1 year] |
| Cellial Technologies | 2002 .11 | 1st round-financing : 1.0 M€, by Finorpa, Nord Innovation, Innovam | RFINA | [1 year] |
| Cellial Technologies | 2001 .01 | Company founded by Prof. Romeo Cecchelli (Institut Pasteur Lille), within Eurasanté Bio-incubator | ORGF | [0 year] |
| CellProthera | 2010 .02 | Nomination : Xavier Lataste, new CEO | ORGN | [1 year] |
| CellProthera | 2008 .06 | Company founded by Philippe Hénon (Prof. University of Haute Alsace) | ORGF | [0 year] |
| CellVax | 2007 .00 | Certification : Eureka award on Oligoclonics | INFO | [5 years] |
| CellVax | 2001 .06 | Company founded by Ming Wei, 2 other biologists, Christian Schatz [Pharm.D.], Olivier-Noël Martin [ex-Sterilyo, founder], and Michel Crépin | ORGF | [0 year] |
| CellVir | 2008 .06 | Seed financing : 2 M€, by Genopole 1er Jour and Inserm Transfert Initiative | SFIN | [2 years] |
| CellVir | 2006 .08 | Patent : granted from Inserm (spin-off) | LEGAL | [0 year] |
| CellVir | 2006 .03 | Company founded by Richard Benarous, Richard Platford, Armand Frydman, E.Thomas Bader, Jean Deregnaucourt | ORGF | [0 year] |
| Cerenis Therapeutics | 2009 .02 | Financing (no interest loan) :2.5 M€ by OSEO Innovation, to finance ongoing clinical development of HDL-related products for the treatment of cardiovascular and metabolic diseases | DEBT | [4 years] |
| Cerenis Therapeutics | 2008 .05 | Clinical trial (phase I) for CER-002, a peroxisome proliferator-activated receptor (PPAR) delta specific agonist (completed) | CLIN | [4 years] |
| Cerenis Therapeutics | 2006 .11 | 2nd round-financing : 42.0 M€, led by TVM Capital, with Orbimed and previous shareholders (53.5 MUS$) | RFINB | [2 years] |
| Cerenis Therapeutics | 2005 .08 | 1st round-financing : 25.0 M€, by Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures | RFINA | [1 year] |
| Cerenis Therapeutics | 2004 .05 | Company founded by Jean-Louis Dasseux and William Brinkerhoff | ORGF | [0 year] |
| Cezanne | 2009 .06 | Partnering research agreement with Brahms (Germany) and Lumiphore (USA), with incorporation of Lumiphore’s complexes into diagnostic tests | R&D | [9 years] |
| Cezanne | 2003 .09 | Partnering sales agreement with Brahms (Germany) as exclusive distributor | MKTG | [3 years] |
| Cezanne | 2003 .09 | Company move to Nîmes, after floods devastated the initial premises in September 2002 | ORGL | [3 years] |
| Cezanne | 2000 .06 | Company founded by Emmanuel Bois and others, in Bagnols-sur-Cèze, to continue the divested diagnostics activities by CisBio International, after their acquisition by Schering AG | ORGF | [0 year] |
| CliniGenetics | 2001 .07 | 1st round-financing : 6.0 M€, by BankInvest, a Danish capital venture group | RFINA | [0 year] |
| CliniGenetics | 2000 .10 | Company founded by a group of cardiovascular research scientists | ORGF | [0 year] |
| Covalab | 2003 .02 | Round-financing : 2.0 M€, searched to finance internal growth (failed) | RFIN | [7 years] |
| Covalab | 1995 .07 | Company founded by Saïd El Alaoui and Vincent Thomas | ORGF | [0 year] |
| Cytheris | 2010 .02 | Patent : granted from U.S. office covering the preparation and uses of its Glycosylated Recombinant Human Interleukin-7 (CYT107) | LEGAL | [11 years] |
| Cytheris | 2009 .06 | Research : publication in Nature Medicine showing that combination of Interleukin-7 with viral vaccine boosts immunity to tumors | R&D | [10 years] |
| Cytheris | 2009 .03 | Clinical trial (phase IIa) for recombinant IL-7 (completed), which induces a dramatic and prolonged CD4 and CD8 T cell expansion, sustained for 48 weeks in HIV patients | CLIN | [10 years] |
| Cytheris | 2008 .07 | Financing (no interest loan) : 1.5 M€, by OSEO, to support its ongoing clinical development program in hepatitis C (HCV) | DEBT | [9 years] |
| Cytheris | 2007 .02 | Clinical trial (phase I) for recombinant IL-7 (beginning) | CLIN | [8 years] |
| Cytheris | 2006 .10 | 2nd round-financing : 24.3 M€, by CDC Innovation with ABN AMRO Capital Life Sciences (today, Forbion) and previous shareholders | RFINB | [7 years] |
| Cytheris | 2005 .05 | Licensing-in of a new immuno-modulating agent for HIV from New York University | LICIN | [6 years] |
| Cytheris | 2003 .00 | Set-up of US subsidiary in Rockville, Maryland | ORGC | [3 years] |
| Cytheris | 2002 .07 | 1st round-financing : 7.0 M€, by Bioam with two Canadian funds, GestionT2C2/Bio and CDP Capital Technology Ventures, plus AXA P.E. and Crédit Agricole P.E. | RFINA | [3 years] |
| Cytheris | 1999 .04 | Licensing-in of Interleukin-7 (IL-7) from Sanofi-Aventis | LICIN | [0 year] |
| Cytheris | 1999 .01 | Company founded by Michel Morre (CEO), as Biotech Inflection Point | ORGF | [0 year] |
| Cytomics | 2008 .03 | Company move to Orsay (from nearby Gif-sur-Yvette) and rename as Cytomics Pharmaceuticals (from Cytomics Systems) | ORGL | [7 years] |
| Cytomics | 2007 .10 | Financing (no interest loan) : 2.1 M€, by OSEO, to support its ongoing program in the anti-fungal area (second Oseo grant) | DEBT | [7 years] |
| Cytomics | 2007 .03 | Nomination : Bernard Cambou, new CEO, Prof. Dominique Thomas, founder, resigns | ORGN | [6 years] |
| Cytomics | 2006 .02 | 2nd round-financing : 10.0 M€, by Edmond de Rotschild I.P., Truffle Venture and previous shareholders | RFINB | [5 years] |
| Cytomics | 2003 .02 | 1st round-financing : 3.0 M€, by Société Générale A.M., and others | RFINA | [2 years] |
| Cytomics | 2000 .04 | Company founded by Dominique Thomas, at initially, Gif-sur-Yvette (near Paris), in collaboration with Richard Benarous (initially as Cytomics Systems, then from February 2008, as Cytomics Pharmaceuticals) | ORGF | [0 year] |
| Cytoo | 2009 .09 | Set-up of Cytoo Inc., US subsidiary (Boston) | ORGC | [1 year] |
| Cytoo | 2009 .07 | 1st round-financing : 3.2 M€ by Auriga Partners and private investor | RFINA | [1 year] |
| Cytoo | 2009 .04 | Launch of Cytoochips, following worldwide exclusivity for adhesive cell micropattern technology from Curie Institute and CNRS (3 patents licensed-in), with on-line trading | MKTG | [0 year] |
| Cytoo | 2009 .01 | Company move to Miniatec (still in Grenoble), with 300 square meters facility | RELOC | [0 year] |
| Cytoo | 2008 .10 | Seed financing : 1.0 M€, by CEA Valorisation, Rhône-Alpes-Création, Expansinvest and private investors (undisclosed) | SFIN | [0 year] |
| Cytoo | 2008 .06 | Company founded by François Chatelain, Alexandra Fuchs, Jacques Lewiner, Michel Bornens | ORGF | [0 year] |
| DBVTechnologies | 2009 .09 | Licensing-out of milk allergy test to Laboratoires Bioprojet for France | LICOUT | [7 years] |
| DBV Technologies | 2009 .01 | 3rd round-financing : 6 M€, by Sofinnova Partners, ALK-Abello (Pharma company) | RFINC | [6 years] |
| DBV Technologies | 2007 .11 | Licensing-out of milk allergy test to Numico (today Danone) | LICOUT | [5 years] |
| DBV Technologies | 2006 .01 | 2nd round-financing : 12.3 M€, by Sofinnova Partners and Apax Partners | RFINB | [3 years] |
| DBV Technologies | 2003 .00 | 1st round-financing : 1.0 M€, by Cap Décisif and Créagro | RFINA | [0 year] |
| DBV Technologies | 2002 .11 | Company founded by Pierre-Henri Benhamou and Bertrand Dupont, with funding from ANVAR, based on new technology led by Prof. Christophe Dupont (AP-HP, Cochin Hospital) | ORGF | [0 year] |
| DNA Therapeutics | 2010 .01 | Patent (2nd) : granted on siDNA by USPTA (further secures the development of its lead product Dbait), followed 1 month later by European Patent Office | LEGAL | [3 years] |
| DNA Therapeutics | 2009 .07 | Financing (no interest loan) : 0.55 M€, by OSEO, to support CMC development of Dbait | DEBT | [3 years] |
| DNA Therapeutics | 2009 .02 | Research : publication in Clinical Cancer Research on Small-molecular drugs mimicking DNA damage (Dbait): a new strategy for sensitizing tumors to radiotherapy | R&D | [2 years] |
| DNA Therapeutics | 2009 .01 | 1st round-financing : 2.2 M€, led by SGAM SEFTI with 2 previous seed investors, Blue Medical Investments and G1J-Île de France | RFINA | [2 years] |
| DNA Therapeutics | 2008 .09 | Seed financing : 0.8 M€, led by Inserm Transfer Initiative, with G1J-Île de France, Blue Medical Investment Group and International Business Angels (parallely to a patent granted on SiDNA) | SFIN | [2 years] |
| DNA Therapeutics | 2007 .05 | Patent : granted on siDNA by USPTA (secures the development of its lead product Dbait) | LEGAL | [0 year] |
| DNA Therapeutics | 2006 .05 | Company founded by Prof. Jian Sheg Sun, from concepts elaborated by Jean-Marc Cosset and Marie Dutreix, in 2001 | ORGF | [0 year] |
| Domain Therapeutics | 2009 .11 | Research : successful completion of the first milestone in its Research Agreement with Takeda Pharmaceutical | R&D | [8 years] |
| Domain Therapeutics | 2008 .12 | 4th round-financing : 2.1 M€ by historical investors (AGF Private Equity, Auriga Partners, Edmond de Rothschild Investment Partners and Sofinnova Partners), followed by Airfi (Alsace Inter Regio Fonds d'Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly | RFIND | [7 years] |
| Domain Therapeutics | 2008 .12 | Company renamed as Domain Therapeutics (from Faust Pharmaceuticals), with Bernard Gilly as President | ORGF | [7 years] |
| Domain Therapeutics | 2008 .01 | Partnering research agreement with Takeda | R&D | [6 years] |
| Domain Therapeutics | 2006 .10 | 3rd round-financing : 8.2 M€, by previous shareholders (bridge financing) | RFINC | [5 years] |
| Domain Therapeutics | 2006 .02 | Nomination : Thomas Seoh as CEO, taking over from founders | ORGN | [4 years] |
| Domain Therapeutics | 2004 .12 | Clinical trial (phase IIa) for FP0011 in ALS and Parkinson's disease (beginning) | CLIN | [3 years] |
| Domain Therapeutics | 2004 .04 | 2nd round-financing : 16.0 M€, by La Compagnie Financière Ed. de Rothschild, Siparex, AGF P.E., FCJE, and previous investors | RFINB | [2 years] |
| Domain Therapeutics | 2003 .12 | Acquisition of Euroclide, with a target oriented technology platform | ACQ+ | [2 years] |
| Domain Therapeutics | 2003 .03 | Company move from Paris to Strasbourg, in the BioValley cluster | ORGL | [1 year] |
| Domain Therapeutics | 2002 .02 | 1st round-financing : 3.0 M€, by Sofinnova Partners and Auriga Partners | RFINA | [0 year] |
| Domain Therapeutics | 2001 .10 | Company founded as Faust Pharmaceuticals by Maurice Israël, Pierre Potier (Taxotere innovator), Pascal Neuville, based in Paris | ORGF | [0 year] |
| Dynabio | 1998 .12 | Nomination : new (undisclosed) Board President | ORGN | [6 years] |
| Dynabio | 1992 .07 | Company founded by unknown entrepreneurs | ORGF | [0 year] |
| EchoSens | 2008 .12 | Nomination : Richard Guillaume, new CEO, replacing Bertrand Fourquet | ORGN | [7 years] |
| EchoSens | 2007 .00 | Set-up of 3 subsidiaries in Spain, Germany and China, more than 330 FibroScan® installed worldwide | ORGC | [5 years] |
| EchoSens | 2004 .00 | Round-financing : undisclosed M€, by OTC and Cap Décisif, beginning of the commercialization of FibroScan with dedicated probe in France | RFIN | [2 years] |
| EchoSens | 2003 .11 | CE mark obtained for FibroScan | MKTG | [2 years] |
| EchoSens | 2001 .06 | Company founded by Sylvain Yon [born 1974], Bertrand Fourquet [Essec, as CEO], Laurent Sandrin, Jean-Michel Hasquenoph [ESTP], supported by ANVAR | ORGF | [0 year] |
| Edelris | 2008 .04 | Partnering research agreement with Roche to provide new compounds services for early stage | R&D | [3 years] |
| Edelris | 2005 .02 | Company founded by Jean-Yves Ortholand, Alfred Greiner, Claude Lardy, Catherine Vidal, Didier Roche, from a R&D activity in Merck Lipha Santé | ORGF | [0 year] |
| Endotis Pharma | 2009 .05 | Clinical trial (phase I) for EP42675, a first in class synthetic parenteral anticoagulant (completed, positive) | CLIN | [6 years] |
| Endotis Pharma | 2008 .01 | 2nd round-financing : 25.0 M€, by the Wellcome Trust | RFINB | [4 years] |
| Endotis Pharma | 2007 .11 | Licensing-out of anti-thrombotics to Akzo Nobel | LICOUT | [4 years] |
| Endotis Pharma | 2007 .06 | Nomination : Charles Woller, new CEO, replacing David Béchard | ORGN | [4 years] |
| Endotis Pharma | 2005 .07 | 1st round-financing : 9.0 M€, by Sofinnova C.V. and others | RFINA | [2 years] |
| Endotis Pharma | 2003 .02 | Company founded by David Béchard (CEO) [Ph.D. oncology, ex-OC&C], Philippe Lassalle [M.D., ex-Roche, Inserm], Franck Vivet [ex-Aventis, Baxter, Fournier] | ORGF | [0 year] |
| Epixis | 2009 .09 | Website under construction since May 2008 | INFO | [6 years] |
| Epixis | 2003 .07 | Company founded by Prof. David Klatzmann [AP-HP], Prof. François-Loïc Cosset [Inserm], Frédéric Tanguy [Institut Pasteur] | ORGF | [0 year] |
| ERYtech Pharma | 2010 .01 | Registration : orphan Drug designation by FDA for GRASPA | MKTG | [5 years] |
| ERYtech Pharma | 2009 .01 | Partnering R&D agreement with American Red Cross to produce Graspa for clinical trials in USA | R&D | [4 years] |
| ERYtech Pharma | 2008 .10 | Clinical trial (phase II) for new vaccine concept against cancer, based on red blood cells, Vaccin’ERY (completed, positive) | CLIN | [3 years] |
| ERYtech Pharma | 2008 .05 | Clinical trial (phase II) for Graspa (orphan drug) in leukemia (completed) | CLIN | [3 years] |
| ERYtech Pharma | 2006 .11 | 1st round-financing : 12.0 M€, by AXA P.E., Auriga Partners, AGF P.E., Capdecisif | RFINA | [2 years] |
| ERYtech Pharma | 2006 .06 | Registration : orphan Drug designation by EMEA for GRASPA | MKTG | [1 year] |
| ERYtech Pharma | 2005 .11 | Clinical trial (phase II) for lead compound in leukemia (beginning) | CLIN | [1 year] |
| ERYtech Pharma | 2005 .10 | Seed financing : 0.75 M€, by Amorçage Rhône Alpes (+ 0.45 M€ from contest by French Ministry of R&D) | SFIN | [0 year] |
| ERYtech Pharma | 2004 .11 | Company founded by Yann Godfrin and Pierre-Olivier Goineau | ORGF | [0 year] |
| Exonhit | 2010 .04 | Acquisition of oncology-focused RedPath Integrated Pathology (USA) to accelerate growth in molecular diagnostics | ACQ+ | [12 years] |
| Exonhit | 2010 .03 | Licensing-out to Allergan and BMS of EHT/AGN001 (a compound already in long term contract with Allergan), with upfront payment of 4 MUS$ | LICOUT | [12 years] |
| Exonhit | 2009 .12 | Public offering (4th) on Alternext : 15.6 M€ | PBO | [12 years] |
| Exonhit | 2009 .11 | Launch of AclarusDx, first diagnostic test in Alzheimer available as a Research Use Only product for Pharma industry (first step) | MKTG | [12 years] |
| Exonhit | 2009 .09 | Clinical trial (phase IIa) for EHT 0202 in Alzheimer’s disease (completed) | CLIN | [11 years] |
| Exonhit | 2009 .07 | Round-financing : 1.45 M€ through the exercise of warrant with existing investors | RFIN | [11 years] |
| Exonhit | 2009 .03 | Proof-of-concept for SpliceArray platform for cancer diagnostic, evidence by I.G.R. (publication in Lancet Oncology) | R&D | [11 years] |
| Exonhit | 2008 .06 | Nomination : Loïc Maurel, as CEO | ORGN | [10 years] |
| Exonhit | 2008 .04 | Nomination : Philippe Rousseau as interim CEO after founders' resignation | ORGN | [10 years] |
| Exonhit | 2007 .06 | Public offering (3rd) on Alternext : 3.4 M€ | PBO | [9 years] |
| Exonhit | 2006 .11 | 5th round-financing : 13.5 M€, in convertible bonds | RFINE | [9 years] |
| Exonhit | 2006 .04 | Public offering (2nd) on Alternext : 6.5 M€ | PBO | [8 years] |
| Exonhit | 2005 .11 | Listing on Alternext : 7.3 M€ | PBO | [8 years] |
| Exonhit | 2004 .02 | 4th round-financing : 8.3 M€ in convertible bonds | RFIND | [6 years] |
| Exonhit | 2001 .12 | Licensing-out to Biomérieux (diagnostics) | LICOUT | [4 years] |
| Exonhit | 2001 .12 | 3rd round-financing : 30.0 M€, by Dresdner Kleinwort, Danske Bank, LCF E. de Rothschild, Sudinnova, and previous shareholders | RFINC | [4 years] |
| Exonhit | 2001 .11 | Licensing-out to Allergan (drugs) | LICOUT | [4 years] |
| Exonhit | 2001 .01 | Set-up of US subsidiary in Maryland | ORGC | [3 years] |
| Exonhit | 2000 .09 | 2nd round-financing : 14.0 M€, by AGF P.E. and BNP P.E. | RFINB | [2 years] |
| Exonhit | 1998 .06 | 1st round-financing : 3.7 M€, by CDC Innovation, Sofinnova, Oxford Bioscience Partners (also, 0.8 M€, by ANVAR) | RFINA | [0 year] |
| Exonhit | 1997 .11 | Company founded by Bruno Tocqué [ex-Rhône Poulenc Rorer], Laurent Bracco [ex-RPR], Fabien Schweighoffer [ex-RPR] | ORGF | [0 year] |
| Eye Tech Care | 2008 .12 | 1st round-financing : 1.2 M€, equally by Crédit Agricole and CEA Valorisation | RFINA | [0 year] |
| Eye Tech Care | 2008 .07 | Company founded by Fabrizio Romano, Philippe Chapuis [born 1968, Eng., ex-EDAP], and Laurent Farcy [Ms.Sc.], based on a platform developed at Inserm 556 unit by Jean-Yves Chapelon and incubated with Crealys | ORGF | [0 year] |
| FlamelTechnologies | 2009 .12 | Clinical trial (phase IIa) of IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection (beginning) | CLIN | [19 years] |
| Flamel Technologies | 2009 .07 | Partnering research agreement with Baxter to formulate Longer Acting Forms of Blood Clotting Factors | R&D | [18 years] |
| Flamel Technologies | 2009 .03 | Financing : € 2.9 Millions ($4 Million) from GlaxoSmithKline (GSK) as a milestone pursuant to the Micropump license agreement for Coreg CR | RFIN | [18 years] |
| Flamel Technologies | 2007 .12 | Partnering research agreement with Merck Serono | R&D | [17 years] |
| Flamel Technologies | 2006 .10 | Registration : FDA approval of Coreg (carvedilol S.R), licensed to GSK | MKTG | [16 years] |
| Flamel Technologies | 2005 .06 | Nomination : Stephen H. Willard as CEO (from CFO in 2000), replacing founder Gérard Soula, after a coup by hedge funds | ORGN | [14 years] |
| Flamel Technologies | 2003 .11 | Licensing-out of Basulin to BMS, with upfront payment of 18 M€ (20.0 MUS$) | LICOUT | [13 years] |
| Flamel Technologies | 2003 .10 | Public offering (Nasdaq) : 56 M€ (62.1 MUS$) | PBO | [13 years] |
| Flamel Technologies | 2002 .07 | Licensing-out of Augmentin delivery-improved to GSK, with upfront payment of 1.3 M€ | LICOUT | [11 years] |
| Flamel Technologies | 2000 .03 | Round-financing : 12.8 M€, by Biotechnology Value Fund, Alta Biopharma, Chase Capital Partners | RFIN | [9 years] |
| Flamel Technologies | 1999 .12 | Licensing-out of Basulin to Novo Nordisk, with upfront payment of 5 M€ and milestones of 37 M€ (rights re-acquired in 2002) | LICOUT | [9 years] |
| Flamel Technologies | 1996 .12 | Listing on Nasdaq : 30 MUS$ (about 23.7 M€) | PBO | [6 years] |
| Flamel Technologies | 1990 .08 | Company founded by Gérard Soula [CEO, ex-Rhône Poulenc R&D], Jean Deléage [Alta Partners, as CEO, Supélec] | ORGF | [0 year] |
| Fluofarma | 2009 .10 | Partnering research agreement with Roche on innovative cell based assays and computational models | R&D | [5 years] |
| Fluofarma | 2009 .07 | Research : publication in Cell Research on outer membrane VDAC1 for permeability transition of the inner mitochondrial membrane | R&D | [5 years] |
| Fluofarma | 2009 .03 | Research : publication in New York Academy of Sciences on new glucocorticoid receptor antagonist with Organon (Schering-Plough, today merged with M.S.D) | R&D | [5 years] |
| Fluofarma | 2008 .10 | Research : publication in Cell Science on Bax redistribution during apoptosis | R&D | [4 years] |
| Fluofarma | 2003 .11 | Company founded by Jean-Baptiste Pin, as a spin-off from the European Institute of Chemistry and Biology (IECB) in Bordeaux, France | ORGF | [0 year] |
| GemacBio | 2008 .01 | Company move from Cenon (Bordeaux eastern suburb) to Berganton, Saint Jean d’Illac, Southwest of Bordeaux | ORGL | [8 years] |
| GemacBio | 2006 .03 | Clinical trial (phase IIa) in Multiple Sclerosis diagnostic (completed) | CLIN | [6 years] |
| GemacBio | 1999 .12 | Company founded by Michel Geffard | ORGF | [0 year] |
| Genepep | 2006 .03 | Partnering research agreement with Skuld-tech | R&D | [3 years] |
| Genepep | 2003 .03 | Company founded by Karine Puget and Jean Martinez (a therapeutic peptide specialist), incubated in the faculty of Pharmacy of Montpellier | ORGF | [0 year] |
| Genewave | 2010 .01 | Company headquarters move from Palaiseau (near Paris) to Paris with R&D facilities in Genopole Evry | ORGL | [8 years] |
| Genewave | 2009 .06 | Financing (no interest loan) : 9.0 M€, by OSEO Innovation, for the NOSOBIO program for prevention, diagnostics and treatment of hospital-acquired infections (with Serial Genetics, Palumed, Da Volterra, Institut Pasteur and Assistance Publique-Hôpitaux de Paris) | DEBT | [7 years] |
| Genewave | 2008 .05 | Launch of HybLive, first real-time micro-array platform | MKTG | [6 years] |
| Genewave | 2008 .01 | Nomination : François X. Desforges as President and Houtaï Choumane as CEO | ORGN | [6 years] |
| Genewave | 2001 .12 | Company founded by Claude Weisbuch (CEO), François Vallet and others | ORGF | [0 year] |
| Genfit | 2010 .02 | Financing (capital increase) : 2.3 M€ on Alternext | PBO | [10 years] |
| Genfit | 2009 .11 | Clinical trial (phase II) for GFT505 (end) in prediabetic patients with atherogenic dyslipidemia and abdominal obesity | CLIN | [10 years] |
| Genfit | 2009 .03 | Licensing-in by acquisition of the research program MKG02 focused on type 2 diabetes and obesity, from Merck Serono | LICIN | [9 years] |
| Genfit | 2009 .02 | Research : new theranostic strategy unveiled with an innovative biomarker technology dedicated to early detection of atherosclerosis | R&D | [9 years] |
| Genfit | 2008 .06 | Financing (no interest loan) : 7.1 M€, by Oseo for IT-Diab programme (drug and diag) with Genoway, SpiBio, Roowin and Academic Institutions, over 5 years | DEBT | [8 years] |
| Genfit | 2008 .04 | Management crisis : direct conflict between 2 co-founders, Jean-François Mouney, CEO and Jean-Charles Fruchart, President of Supervisory Board (dismissed) | ORG | [8 years] |
| Genfit | 2006 .12 | Listing on Alternext : 15.0 M€ | PBO | [7 years] |
| Genfit | 2006 .05 | Clinical trial (phase II) for first lead, GFT14 (beginning) | CLIN | [6 years] |
| Genfit | 2003 .00 | Set-up of international offices in Cambridge (USA) | ORGC | [3 years] |
| Genfit | 2000 .03 | Seed financing : 2 M€, by UCB, Aventis, Sanofi-Synthelabo, Merck-Lipha, Finorpa, Nord Création, BP Création | SFIN | [0 year] |
| Genfit | 1999 .09 | Company founded by Prof. Jean-Charles Fruchart (born 1945), Jean-François Mouney, Prof. Bart Staels, Florence Séjourné | ORGF | [0 year] |
| GenOdyssee | 2008 .02 | Patent : notice of Allowance of US Application for lead compound (Interferon alpha variant 17) | LEGAL | [8 years] |
| GenOdyssee | 2006 .10 | Partnering research agreement with Baxter on therapeutic proteines derived from natural genetiques variations | R&D | [7 years] |
| GenOdyssee | 2000 .05 | 1st round-financing : 8.1 M€, led by Matignon I.F., with Edmond de Rotschild Fin., Société Générale A.M., George Cohen | RFINA | [0 year] |
| GenOdyssee | 1999 .10 | Company founded by Jean-Louis Escary (the first company incubated at Evry Genopole) | ORGF | [0 year] |
| Genomic Vision | 2010 .02 | Financing (subsidy) : 0.25 M€ from AFM to develop a routine clinical test for FSHD (dystrophia) | RFIN | [5 years] |
| Genomic Vision | 2008 .10 | Financing (no interest loan) : 1.1 M€, by OSEO Innovation, on an antiviral programme (partnered with Cellectis, which gets 7.5 M€) | DEBT | [4 years] |
| Genomic Vision | 2008 .07 | 2nd round-financing : 4.0 M€, by Vesalius BioCapital and previous shareholder Société Générale Asset Management Alternative Investments (SGAM AI) | RFINB | [4 years] |
| Genomic Vision | 2005 .11 | 1st round-financing : 2.0 M€, by Société Générale Asset Management (SGAM) | RFINA | [1 year] |
| Genomic Vision | 2004 .07 | Company founded by Aaron Bensimon (board chairman, CEO) and Daniel Nerson (COO) | ORGF | [0 year] |
| GenoSafe | 2008 .11 | Nomination : Didier Caizergues as Board President and CEO, replacing Anne-Marie Masquelier | ORGN | [5 years] |
| GenoSafe | 2006 .11 | Financing : grant of 3.5 M€, by A2i (Oseo), coordinated by Mérieux Alliance, within ADNA project | DEBT | [3 years] |
| GenoSafe | 2005 .06 | Nomination : Anne-Marie Masquelier, as CEO (plus, President, in 2006) | ORGN | [1 year] |
| GenoSafe | 2003 .09 | Company founded by Genethon and AFM (Association Française pour les Myopathies, i.e. French Muscular Dystrophy Association) | ORGF | [0 year] |
| GenoScience Pharma | 2006 .11 | Acquisition of Genosedi, a bio-informatics venture | ACQ+ | [5 years] |
| GenoScience Pharma | 2001 .08 | Company founded by Prof. Philippe Halfon | ORGF | [0 year] |
| Genoscreen | 2009 .04 | Launch of new MIRU-VNTR typing kit for Mycobacterium tuberculosis complex (kits, training and software tool, based in client's premises) | MKTG | [8 years] |
| Genoscreen | 2006 .00 | Launch of new standardised MIRU-VNTR genotyping service for Mycobacterium tuberculosis (in-house based, from client's samples) | MKTG | [4 years] |
| Genoscreen | 2001 .01 | Company founded by André Tordeux, as a spin-off from Institut Pasteur (Lille) | ORGF | [0 year] |
| GenOway | 2010 .05 | Partnering research agreement with Griffith University (Australia) for olfactory stem cells technology | R&D | [11 years] |
| GenOway | 2009 .10 | Licensing-in of Flex technology, developed by Prof. Pierre Chambon and Dr Norbert Ghyselinck at the IGBMC (Strasbourg) | LICIN | [10 years] |
| GenOway | 2009 .02 | Launch of StemCellHY, a new production technology including ThromboGenics' proprietary stem cell lines | MKTG | [9 years] |
| GenOway | 2008 .06 | Financing (no interest loan) : 7.1 M€, by Oseo for IT-Diab programme (drug and diag) with Genfit, SpiBio, Roowin and Academic Institutions, over 5 years | DEBT | [9 years] |
| GenOway | 2007 .00 | Partnering research agreement with Boehringer Ingelheim (USA) to provide murine models | R&D | [7 years] |
| GenOway | 2007 .05 | Seed financing : 1.1 M€, by NGFN (National Genome Research Network) in Germany | SFIN | [8 years] |
| GenOway | 2007 .05 | Listing on Alternext : 6.2 M€ (23% of shares) | PBO | [8 years] |
| GenOway | 2006 .05 | Partnering distribution agreement with Charles River (USA market, co-promotion) | MKTG | [7 years] |
| GenOway | 2005 .00 | Acquisition of Murinus (Germany) | ACQ+ | [5 years] |
| GenOway | 2004 .09 | 2nd round-financing : 4.0 M€, led by CDC Entreprises, Siparex Ventures | RFINB | [5 years] |
| GenOway | 2003 .04 | 1st round-financing : 3.5 M€, led by Dassault Developpement, with Qualis, Rhône Alpes Création | RFINA | [4 years] |
| GenOway | 1999 .03 | Company founded by Alexandre Fraichard and Gilles de Poncins, as a spin-off from Normale Sup (Lyon) | ORGF | [0 year] |
| Genticel | 2010 .03 | 3rd round-financing : 13.1 M€, led by AGF Private Equity, with 3 new investors, IRDI (Institut Régional de Développement Industriel), Amundi Private Equity Funds and InnoBio fund, managed by CDC Entreprises, and previous investors, including Edmond de Rothschild Investment Partners (EdRIP) | RFINC | [8 years] |
| Genticel | 2010 .02 | Company name change from BT Pharma to Genticel | INFO | [8 years] |
| Genticel | 2008 .09 | 2nd round-financing : 2.8 M€ mainly by Edmond de Rothschild Investment Partners, followed by Fonds d'Amorçage Midi-Pyrénées | RFINB | [6 years] |
| Genticel | 2007 .09 | Clinical trial (phase I) for Procervix, HPV vaccine (beginning) | CLIN | [5 years] |
| Genticel | 2007 .05 | 1st round-financing : 1.3 M€, mainly by Institut Pasteur and an undisclosed private investor | RFINA | [5 years] |
| Genticel | 2001 .10 | Company founded by Benedikt Timmerman, as a spin-off from Institut Pasteur (Paris) | ORGF | [0 year] |
| GTP Technology | 2010 .04 | Launch of catalogue of recombinant proteins for research, ready-to-use proteins and on demand proteins | MKTG | [9 years] |
| GTP Technology | 2006 .06 | Certification : approval by regional Cancer-Bio-Santé cluster of L. lactis research program | INFO | [5 years] |
| GTP Technology | 2005 .04 | Launch of Eiffel Biostructure platform with two partners, AliX and NMRtec, to extend services to structural analysis | MKTG | [4 years] |
| GTP Technology | 2004 .12 | Seed financing : 0.45 M€, by undisclosed investors | SFIN | [4 years] |
| GTP Technology | 2003 .12 | Partnering supply agreement with Pierre Fabre on recombinant protein | R&D | [3 years] |
| GTP Technology | 2003 .01 | Company move from Toulouse base to Labège (near Toulouse) | ORGL | [2 years] |
| GTP Technology | 2000 .10 | Company founded by Éric Devic, as a spin-off from the Protein Engineering Department of P. Sabatier University in Toulouse, France | ORGF | [0 year] |
| HeliosBiosciences | 2009 .00 | Research : selection for validation of 3 of the 6 immunosuppressives targets with Immuno-Dyn, with peptides used to transfect lymphocytes | R&D | [6 years] |
| Helios Biosciences | 2005 .06 | Research : finalization of first large-scale dynamic model of human T-lymphocyte | R&D | [3 years] |
| Helios Biosciences | 2002 .05 | Company founded by Jean-Baptiste Dumas (CEO), with name shortened as HBS | ORGF | [0 year] |
| Hybrigenics | 2009 .12 | Financing : 2.735 M€ issued for private investors, i.e. 10.5% capital, for inecalcitol development costs (in complement to Yorkville) | RFIN | [11 years] |
| Hybrigenics | 2009 .09 | Financing : up to 5 M€ through privileged new shares to Yorkville, over 3 years | RFIN | [11 years] |
| Hybrigenics | 2009 .09 | Partnering research agreement with yeast two-hybrid contract of 1.5 M€, for services to an American multinational life sciences company during 3 years | R&D | [11 years] |
| Hybrigenics | 2009 .05 | Set-up of Hybrigenics Services, a subsidiary owned by Rémi Delansorne | ORGC | [11 years] |
| Hybrigenics | 2009 .02 | Financing : 0.4 M€ by E.U. to participate in Masterswitch European project and screen inhibitors of protein interaction in the field of chronic inflammatory diseases | RFIN | [11 years] |
| Hybrigenics | 2008 .12 | Patent : granted on protease inhibitors specific to ubiquitin (cancer) | LEGAL | [10 years] |
| Hybrigenics | 2008 .09 | Financing (no interest loan) : 1.4 M€, by OSEO, to support its ongoing clinical development program of inecalcitol in prostate cancer | DEBT | [10 years] |
| Hybrigenics | 2007 .12 | Listing on Alternext : 6.2 M€ | PBO | [9 years] |
| Hybrigenics | 2005 .09 | Nomination : Rémi Delansorne, as CEO (previously CSO since 2004), replacing Donny Strosberg | ORGN | [7 years] |
| Hybrigenics | 2003 .05 | Acquisition of Semaia (Holland), a biotech focused on oncology | ACQ+ | [5 years] |
| Hybrigenics | 2002 .04 | 3rd round-financing : 16.8 M€, led by Life Science Partners, with Banexi V.P., C.F. Edmond de Rothschild, and previous shareholders | RFINC | [4 years] |
| Hybrigenics | 2000 .10 | 2nd round-financing : 19.5 M€, led by Alafi Capital, Lombard Odier, Medicis, Rendex, Sofindev, and previous shareholders | RFINB | [2 years] |
| Hybrigenics | 1999 .06 | 1st round-financing : 9.1 M€, led by Auriga Partners, IMH, HealthCap, and previous shareholders | RFINA | [1 year] |
| Hybrigenics | 1998 .05 | Seed financing : 1 M€, by Apax Partners, Altamir | SFIN | [0 year] |
| Hybrigenics | 1998 .04 | Licensing-in of any discovery by Institut Pasteur on protein-protein interaction, with right of first refusal and exclusivity | LICIN | [0 year] |
| Hybrigenics | 1998 .01 | Company founded by Prof. Arthur Donny Strosberg (CEO), Pierre Legrain, Jacques Camonis, and Richard Benarous | ORGF | [0 year] |
| Hyphen BioMed | 1999 .01 | Company founded by Jean Amiral and Anne Marie Vissac, in the venture incubator of Conflans-Sainte-Honorine (near Paris) | ORGF | [0 year] |
| Imagene | 2009 .05 | Inauguration of new industrial platform in Evry for long-term DNA encapsulation | INDUS | [10 years] |
| Imagene | 2006 .12 | 1st round-financing : 2.0 M€, by OTC A.M. and Aquitaine Création Investissement, to build a production facility | RFINA | [8 years] |
| Imagene | 1998 .12 | Company founded by a multi-disciplinary team of scientists, including Sophi Tuffet (CEO), with a world patent | ORGF | [0 year] |
| ImmunId | 2009 .11 | Partnering development agreement with Roche Diagnostics to standardize immuno-monitoring in molecular biology | R&D | [4 years] |
| ImmunId | 2009 .05 | 1st round-financing : 2.4 M€, by Vizille Capital Innovation (Vizille Capital Innovation & Sudinnova), SOFIMAC Partners and CEA Investissement | RFINA | [4 years] |
| ImmunId | 2009 .05 | Launch of Platine, a joint immuno-monitoring platform, by 5 partners (Innate Pharma, Transgene, ImmunID, Inserm and Cancer Centre Léon-Bérard), based in Lyon | MKTG | [4 years] |
| ImmunId | 2008 .12 | Financing (no interest loan) : 1.6 M€, by OSEO, to support its clinical development program of validation NDL biomarker and ImmunTraCkeR diagnostic test | DEBT | [3 years] |
| ImmunId | 2008 .09 | Licensing-in of a genomic analytical process from CEA and INSERM | LICIN | [3 years] |
| ImmunId | 2008 .01 | Partnering research agreement with Sanofi Pasteur | R&D | [2 years] |
| ImmunId | 2007 .07 | Certification : ISO 9001-2000 | INFO | [2 years] |
| ImmunId | 2005 .03 | Company founded by Nicolas Pasqual and Sébastien Weisbuch, for immunomonitoring and diagnostic solutions | ORGF | [0 year] |
| Immutep | 2009 .01 | Clinical trial (phase II interim) for ImmuFact IMP321 associated with paclitaxel doubles clinical response rate in Metastatic Breast Cancer (confirmed in January 2010, with final results) | CLIN | [7 years] |
| Immutep | 2008 .10 | Registration : FDA IND allowance for IMP321 in Pancreatic Cancer | MKTG | [7 years] |
| Immutep | 2005 .04 | Clinical trial (phase II) for IMP321 (beginning) | CLIN | [3 years] |
| Immutep | 2005 .01 | 2nd round-financing : 2.5 M€, by Innoven, for the lead compound IMP321 (immuno-stimulation factor) | RFINB | [3 years] |
| Immutep | 2003 .12 | 1st round-financing : 2.5 M€, by FCPI La Poste Innovation, Innoven | RFINA | [2 years] |
| Immutep | 2001 .09 | Company founded by Prof. Frédéric Triebel and John B. Hawken, as a spin-off from Institut Gustave Roussy (the largest cancer center clinic in Europe, located South of Paris) and Serono (today Merck-Serono) | ORGF | [0 year] |
| Imstar | 2010 .01 | Partnering research agreement, Biotype, with Sanofi Aventis and 4 academic labs, CEA, Institut Pasteur, Armines and Assitance Publique-Hôpitaux de Paris (AP-HP), to develop new approaches in prostate cancer (completed after 30 months) | R&D | [24 years] |
| Imstar | 2008 .10 | Research : publication in Mutagenesis with validation of the automated scoring for Micronucleus assay using IMSTAR Pathfinder technology on human lymphocytes | R&D | [23 years] |
| Imstar | 2008 .05 | Partnering distribution agreement with Naturegene for China market | MKTG | [22 years] |
| Imstar | 1997 .00 | Launch of Pathfinder, for automated digital imaging | MKTG | [11 years] |
| Imstar | 1985 .09 | Company founded by Françoise Soussaline, as a spin-off from CEA | ORGF | [0 year] |
| In-Cell-Art | 2008 .08 | Partnering research agreement with Sanofi Pasteur, to evaluate Incellart technologies of nanocarriers | R&D | [22 years] |
| In-Cell-Art | 2005 .08 | Company founded by Prof. Jean-Marie Lehn (Nobel Prize), Prof. Pierre Lehn, Bruno Pitard | ORGF | [19 years] |
| Indicia Biotechnology | 2010 .05 | Partnering research agreement with Singulex (USA) on biomarker quantification at the femtogram level to provide ultrasensitive and early biomarker detection through Erenna Immunoassay System | R&D | [11 years] |
| Indicia Biotechnology | 2009 .09 | Research : launch of Gliadys project, in collaboration with IDD Biotech, based on therapeutic antibodies against different glioma forms | R&D | [11 years] |
| Indicia Biotechnology | 2008 .03 | Acquisition of Axcell Biotech to strengthen OEM commercial position | ACQ+ | [9 years] |
| Indicia Biotechnology | 1998 .07 | Company founded by Stéphane Legastelois | ORGF | [0 year] |
| InGen Biosciences | 2009 .03 | Company rename as InGen Biosciences (from Abag) | ORGL | [7 years] |
| InGen Biosciences | 2008 .12 | Nomination : Jean-Pierre Hermet, new CEO | ORGN | [7 years] |
| InGen Biosciences | 2006 .07 | Acquisition of Ingen, a distribution company founded in 1993 | ACQ+ | [4 years] |
| InGen Biosciences | 2006 .02 | 2nd round-financing : 6.0 M€, by new investor, Innoven (followed by Société Générale A.M.) | RFINB | [4 years] |
| InGen Biosciences | 2003 .03 | 1st round-financing : 2.0 M€, by Société Générale A.M. | RFINA | [1 year] |
| InGen Biosciences | 2001 .12 | Company founded by Marc Bourlioux and Jean-Louis Gaillard, as AbAg | ORGF | [0 year] |
| Innate Pharma | 2009 .12 | 5th round-financing : 23.1 M€, by FSI (for 11 M€) and previous investors (Novo Nordisk and Alta Partners) | RFINE | [10 years] |
| Innate Pharma | 2009 .08 | Clinical trial (phase II, beginning) for monoclonal antibody IPH 2101, supported by 2.9 M€ financing from Oséo | CLIN | [9 years] |
| Innate Pharma | 2009 .06 | Clinical trial (phase IIa, positive) for IPH1101 in type C Hepatitis | CLIN | [9 years] |
| Innate Pharma | 2009 .05 | Launch of Platine, a joint immuno-monitoring platform, by 5 partners (Innate Pharma, Transgene, ImmunID, Inserm and Cancer Centre Léon-Bérard), based in Lyon | MKTG | [9 years] |
| Innate Pharma | 2009 .01 | Partnering research agreement with Vivalis to produce IPH 4101 with EB66 for clinical trials (Oseo debt financing grant of 3.0 M€ for Innate Pharma) | R&D | [9 years] |
| Innate Pharma | 2008 .04 | Set-up of US subsidiary (operations) in New York State | ORGC | [8 years] |
| Innate Pharma | 2008 .02 | Set-up of 2 subsidiaries (trade, production) in France | ORGC | [8 years] |
| Innate Pharma | 2007 .05 | Nomination : Gilles Brisson, new Board Chairman, ex-Chairman Supervisory Board at Aventis Pharma France | ORGN | [7 years] |
| Innate Pharma | 2007 .01 | Launch of PGX Predict (diagnostics) by Clinical Data Inc., US partner | MKTG | [7 years] |
| Innate Pharma | 2006 .11 | Listing on Eurolist by Euronext Paris : 33.7 M€ | PBO | [7 years] |
| Innate Pharma | 2006 .00 | 4th round-financing : 10.0 M€, by Novo Nordisk | RFIND | [6 years] |
| Innate Pharma | 2006 .06 | Licensing-in of lead compound (TLR) from Schering-Plough | LICIN | [6 years] |
| Innate Pharma | 2006 .03 | Licensing-out to Novo Nordisk (total of 15.0 M€ equity investment, including 2003 deal) | LICOUT | [6 years] |
| Innate Pharma | 2004 .07 | 3nd round-financing : 15.0 M€, by Novo Nordisk, Quilvest and NIF Ventures | RFINC | [4 years] |
| Innate Pharma | 2003 .11 | Licensing-out to Novo Nordisk for the generation of a new therapeutic class of immuno-modulatory antibodies targeting natural killer (NK) cells | LICOUT | [4 years] |
| Innate Pharma | 2002 .08 | 2nd round-financing : 20.0 M€, by Alta Partners and AXA P.E., with Gilde Biotech & Nutrition, Pechel Industries, Innoveris | RFINB | [2 years] |
| Innate Pharma | 2002 .05 | Clinical trial (phase I) for Innacell and Phosphotim (beginning) | CLIN | [2 years] |
| Innate Pharma | 2002 .02 | Financing (no interest loan) : 2.0 M€, by ANVAR, to support initial clinical trials | DEBT | [2 years] |
| Innate Pharma | 2000 .04 | 1st round-financing : 4.5 M€, led by Sofinnova Partners, with Auriga Partners, GIMV | RFINA | [0 year] |
| Innate Pharma | 1999 .10 | Company founded by 4 European Scientists, pioneers in the field of innate immunity (Alessandro Moretta, Marc Bonneville, Jean-Jacques Fournier and Eric Vivier) and 2 managers from the biopharmaceutical industry (Hervé Brailly and François Romagné) | ORGF | [0 year] |
| InnaVirVax | 2010 .01 | Research : selection of VAC3S its first vaccine candidate for development and initiation of non clinical development | R&D | [1 year] |
| InnaVirVax | 2009 .06 | 1st round-financing : 1.1 M€, by Cap Décisif Management and Genopole 1er Jour | RFINA | [1 year] |
| InnaVirVax | 2008 .07 | Seed financing : 0.45 M€, as a grant by French Ministry of Research and Higher Education (followed by a grant of 1.7 M€ by ANR) | SFIN | [0 year] |
| InnaVirVax | 2008 .03 | Company founded by undisclosed entrepreneurs, based on research by Prof. Patrice Debré and Dr Vincent Vieillard (INSERM U945, AP-HP Pitié-Salpétrière, University Pierre & Marie Curie) | ORGF | [0 year] |
| Innovative Health Diagnostics | 2009 .04 | Round-financing : 1.8 M€ in preparation | RFIN | [0 year] |
| Innovative Health Diagnostics | 2009 .02 | Company founded by Xavier Regnaut, Jean de Barry, François Sellal | ORGF | [0 year] |
| IntegraGen | 2010 .04 | Research : positive results on combined analysis of several options in a genetic score to identify individuals with high risks of developing autisme | R&D | [9 years] |
| IntegraGen | 2010 .02 | Licensing-out to Transgenomic to develop and distribute its genetic test of autisme in USA | LICOUT | [9 years] |
| IntegraGen | 2010 .01 | Licensing-in of technology to set-up a service lab in genetic analysis and a demo lab in Europe, from Fluidigm (USA) | LICIN | [9 years] |
| IntegraGen | 2009 .06 | Partnering research agreement with Servier for genotyping applications in Servier's Genese clinical trial | R&D | [8 years] |
| IntegraGen | 2007 .09 | Nomination : Bernard Courtieu as CEO, replacing Jan Mous | ORGN | [7 years] |
| IntegraGen | 2006 .12 | Set-up of US subsidiary (operations) in New York State | ORGC | [6 years] |
| IntegraGen | 2006 .11 | 3rd round-financing : 2.0 M€, by Royal DSM, within a research agreement to develop molecular diagnostics | RFINC | [6 years] |
| IntegraGen | 2005 .11 | 2nd round-financing : 8.0 M€, by AGF P.E., Société Générale A.M., and previous shareholders | RFINB | [5 years] |
| IntegraGen | 2004 .01 | Research : discovery of a human gene linked to autism | R&D | [3 years] |
| IntegraGen | 2003 .07 | Nomination : Jan Mous as CEO [born 1950, Ph.D., ex-Lion Bioscience AG, as CSO, Roche], replacing Jean-Luc Gerbier | ORGN | [3 years] |
| IntegraGen | 2001 .06 | 1st round-financing : 6.3 M€, by CDC Innovation, GenAvent, Bioam, Bay Tech | RFINA | [0 year] |
| IntegraGen | 2000 .03 | Company founded by Philippe Gesnouin (CIO), Jörg Hager, Anne Philippi, Nathalie Vionnet, Jean-Luc Gerbier [CEO, ex-BMS, Biostar], Peter Brooks, as a spin-off from CNG (Centre National du Génotypage) | ORGF | [0 year] |
| Ipsogen | 2010 .01 | Licensing-in (option) on rights of TET2 abnormalities to improve the diagnosis of Blood-based Disorders, owned by a consortium of 7 public institutions led by IGR&D (IGR) | LICIN | [10 years] |
| Ipsogen | 2009 .12 | Partnering research agreement with Institut Curie, on Genomic Grade, a molecular diagnostic tool for breast cancer | R&D | [10 years] |
| Ipsogen | 2009 .06 | Financing : 2.5 M€ reserved capital increase | RFIN | [9 years] |
| Ipsogen | 2008 .11 | Launch of MapQuant Dx, a new test to determine tumor HER2 status and guide Herceptin prescription in breast cancer (Europe) | MKTG | [9 years] |
| Ipsogen | 2008 .08 | Licensing-out to Quest Diagnostics for the use of the JAK2 V617F mutation into Quest kits in USA researche centers (non-exclusive, followed by Arup, alos for uSA, in May 2009) | LICOUT | [8 years] |
| Ipsogen | 2008 .06 | Listing on Alternext : 11.8 M€, i.e. 35% of shares (oversubscribed) | PBO | [8 years] |
| Ipsogen | 2007 .11 | 3rd round-financing : 2.0 M€, by Connecticut Innovations, and previous shareholders | RFINC | [8 years] |
| Ipsogen | 2005 .03 | Set-up of US subsidiary (operations) in Connecticut State | ORGC | [5 years] |
| Ipsogen | 2005 .02 | 2nd round-financing : 3.5 M€, by previous shareholders | RFINB | [5 years] |
| Ipsogen | 2001 .07 | 1st round-financing : 4.5 M€, led by Société Générale A.M., with Matignon Technologies, Innovéris | RFINA | [1 year] |
| Ipsogen | 1999 .09 | Company founded by Vincent Fert (CEO), Stéphane Debono, Fabienne Hermitte | ORGF | [0 year] |
| I-Stem | 2009 .06 | Partnering research agreement of 7.5 M€ within 2 years with Roche (Swiss), to initiate their teams to I-Stem proprietary technology | R&D | [4 years] |
| I-Stem | 2007 .01 | Set-up of mixed Inserm-UEVE (Université d’Évry-Val d’Essonne) R&D unit | ORGC | [2 years] |
| I-Stem | 2004 .12 | Company founded (without legal entity) by INSERM and AFM (French Muscular Dystrophy Association), as Institute for Stem cell Therapy and Exploration of Monogenic diseases (I-Stem) | ORGF | [0 year] |
| Karcinolys | 2007 .06 | Round-financing : 8 M€ (planned) | RFIN | [1 year] |
| Karcinolys | 2005 .12 | Company founded by Jean-Luc Béjot [ex-Opi], Jean-Baptiste de Cabanes, Jacques de Massignac | ORGF | [0 year] |
| Keosys | 2008 .12 | Launch of new 3D Fusion PACS Viewer system, allowing to distribute volumic exams to any desktop in the hospital and to review them with Keosys 3D Fusion viewer | MKTG | [7 years] |
| Keosys | 2008 .09 | Round-financing : 1.5 M€, by Vizille Capital Innovation (CIC group), Pays de Loire Développement and Lumiplan | RFIN | [7 years] |
| Keosys | 2006 .00 | Seed financing : undisclosed M€, by Sodera (10% capital share) | SFIN | [4 years] |
| Keosys | 2004 .00 | Seed financing : undisclosed M€, by Région Pays de Loire (partly in place of historic shareholder Lumiplan) | SFIN | [2 years] |
| Keosys | 2002 .00 | Launch of Positoscope, a new display tool of digital imaging for Nuclear medicine, aimed to increase distant cooperation between doctors | MKTG | [0 year] |
| Keosys | 2001 .01 | Company founded by Jérôme Fortineau, with 3 engineers, as a SSII and a subsidiary of Lumiplan with IT activities | ORGF | [0 year] |
| LibraGen | 2010 .01 | Sustainable process intensification in the manufacturing of its cosmetic actives, Inoveol | MKTG | [8 years] |
| LibraGen | 2008 .12 | Launch of Inoveol (www.inoveol.com) actives (stable polyphenol cosmetic compounds) on the US market | MKTG | [7 years] |
| LibraGen | 2008 .09 | Partnering research agreement with DSM, to co-develop transaminases for production of chiral amines | R&D | [7 years] |
| LibraGen | 2006 .01 | Partnering research agreement with Pierre Fabre, enzymatic synthesis | R&D | [4 years] |
| LibraGen | 2005 .11 | Partnering research agreement with Minakem on biocatalysis and organic synthesis (green chemistry, fine chemicals) | R&D | [4 years] |
| LibraGen | 2005 .06 | Nomination : Fabrice Lefèvre, as CSO | ORGN | [4 years] |
| LibraGen | 2004 .09 | Company move from Lyon to Toulouse | ORGL | [3 years] |
| LibraGen | 2004 .05 | 1st round-financing : 2.2 M€, by BIOAM, Galia Gestion, and IRDI (Midi Pyrénées V.C.) | RFINA | [3 years] |
| LibraGen | 2001 .03 | Seed financing : 0.75 M€, by Bioam | SFIN | [0 year] |
| LibraGen | 2001 .02 | Company founded by Renaud Nalin and Pascal Simonet [CNRS] in Lyon | ORGF | [0 year] |
| Magnisense | 2008 .10 | Clinical trial positive, to view and characterize tissue lining the common bile duct at a microscopic level in real time with Cellvizio device, the world's smallest microscope | CLIN | [5 years] |
| Magnisense | 2008 .04 | Launch of MIAplex, a multiparametric magnetic technology | MKTG | [4 years] |
| Magnisense | 2008 .03 | Company expansion with new laboratories facility in Dardilly (near Lyon) | ORGC | [4 years] |
| Magnisense | 2007 .04 | Patent : filed for the invention of a new multiparametric magnetic immunoassay | LEGAL | [3 years] |
| Magnisense | 2007 .02 | Partnering development agreement with Indicia Biotechnology for joint testing platform of magnetic marker-based in vitro diagnostics | R&D | [3 years] |
| Magnisense | 2006 .12 | Nomination : Luc Lenglet, as CEO | ORGN | [3 years] |
| Magnisense | 2006 .06 | 2nd round-financing : undisclosed M€, by Baring Vostok Capital Partners and private investors | RFINB | [3 years] |
| Magnisense | 2006 .03 | Patent : filed to protect special features of adapted lateral flow membrane cartridges | LEGAL | [2 years] |
| Magnisense | 2003 .07 | Patent : filed to protect a special embodiment of the technology | LEGAL | [0 year] |
| Magnisense | 2003 .06 | 1st round-financing : undisclosed M€, by Baring Vostok Capital Partners and private investors | RFINA | [0 year] |
| Magnisense | 2003 .05 | Company founded by Baring Vostok Capital Partners and private investors, from technical development carried out jointly with the Russian Academy of Sciences in Moscow and Bertin technologies in France for engineering | ORGF | [0 year] |
| Mapreg | 2008 .03 | Round-financing : in preparation, with nomination of next CEO | RFIN | [7 years] |
| Mapreg | 2008 .02 | Registration : orphan Drug designation by EMEA for MAP4343 (trauma of spinal cord) | MKTG | [7 years] |
| Mapreg | 2000 .10 | Company founded by Etienne Emile Baulieu and his team at Kremlin-Bicêtre hospital (Paul Robel, Arlette Fellous, Pascal Azadian), within Inserm premises and support | ORGF | [0 year] |
| MAT Biopharma | 2009 .01 | Nomination : François Vallet, as CEO | ORGN | [8 years] |
| MAT Biopharma | 2008 .09 | Clinical trial (phase II) for Ferritarq (completed) | CLIN | [8 years] |
| MAT Biopharma | 2006 .09 | Registration : orphan Drug designation by EMEA for Ferritarq | MKTG | [6 years] |
| MAT Biopharma | 2006 .02 | Partnering research agreement with Pierre Fabre, on anticancer MABs | R&D | [6 years] |
| MAT Biopharma | 2005 .01 | Partnering research agreement with Servier, on anticancer MABs | R&D | [4 years] |
| MAT Biopharma | 2002 .11 | Round-financing : 1.25 M€, by undisclosed investors | RFIN | [2 years] |
| MAT Biopharma | 2000 .02 | Company founded by Dr Jean Kadouche [born 1945, initial CEO], Raphaël Lévy [M.D., Laennec], Bernard Montanari (initially named Monoclonal Antibodies Therapeutics) | ORGF | [0 year] |
| Mauna Kea Technologies | 2009 .03 | Partnering sales agreements with VisualSonics to sell Mauna Kea Technologies’ Cellvizio LAB on a Worldwide Basis to Animal Imaging Market | MKTG | [8 years] |
| Mauna Kea Technologies | 2008 .12 | Partnering sales agreements on Cellvizio with Diagmed Healthcare Limited (UK), EndoTécnica (Spain and Greece), RMS Endoscopy (Belgium) | MKTG | [8 years] |
| Mauna Kea Technologies | 2008 .01 | 3rd round-financing : 20.5 M€, by U.S.-based Psilos Group, joined by Seventure and by previous shareholder CreAdev | RFINC | [7 years] |
| Mauna Kea Technologies | 2007 .03 | Partnering sales agreement on Cellvizio with Leica Microsystems to benefit researchers using Leica FCM1000 with Cellvizio technology | MKTG | [6 years] |
| Mauna Kea Technologies | 2006 .11 | Partnering sales co-promotion agreement with Invitrogen for In Vivo Imaging Solutions in USA | MKTG | [6 years] |
| Mauna Kea Technologies | 2006 .05 | Launch of Cellvizio-GI at Digestive Disease Week 2006 in Los Angeles (USA) | MKTG | [6 years] |
| Mauna Kea Technologies | 2000 .05 | Company founded by Sacha Loiseau and Benjamin Abrat, under the name Mauna Kea which means «white mountain» in Hawai | ORGF | [0 year] |
| Medesis Pharma | 2009 .12 | Registration : orphan Drug positive opinion by EMEA for treatment of Huntington's disease (NP03) | MKTG | [6 years] |
| Medesis Pharma | 2008 .04 | Financing (no interest loan) : 0.9 M€, by OSEO and Languedoc-Roussillon region, to support its ongoing program for NP01 in diabetes | DEBT | [5 years] |
| Medesis Pharma | 2008 .01 | Company move from Paris to Baillargues (10km from Montpellier) | ORGL | [4 years] |
| Medesis Pharma | 2006 .01 | Clinical trial planned, after first preclinical trial results on NP01 on metabolic syndrome | CLIN | [2 years] |
| Medesis Pharma | 2003 .04 | Company founded by Jean-Claude Maurel, headquartered in Baillargues (today : labs location) | ORGF | [0 year] |
| Mellitech | 2009 .10 | Proof-of-concept for lead ZnT8 agonist compound : insulin secretion enhanced in normal WT mice and unchanged in mice knocked-out for the slc30a8 gene | R&D | [4 years] |
| Mellitech | 2009 .06 | Round-financing : 0.3 M€, by business angels | RFIN | [3 years] |
| Mellitech | 2009 .03 | Nomination : Richard Platford, as CEO, replacing Philippe Barth | ORGN | [3 years] |
| Mellitech | 2007 .12 | Seed financing : 0.5 M€, by business angels | SFIN | [2 years] |
| Mellitech | 2006 .11 | Nomination : Philippe Barth, as CEO | ORGN | [1 year] |
| Mellitech | 2005 .10 | Company founded by Pierre-Marie Girod-Roux, Michel Sève, Yann de Boysson, as a spin-off from UJF (Université Joseph Fournier) and CEA | ORGF | [0 year] |
| Metabolys | 2009 .01 | Financing : expression of interest, first call IMI | RFIN | [0 year] |
| Metabolys | 2008 .11 | Company founded by Gabriel Baverel, as a spin-off from Claude-Bernard University, in Lyon | ORGF | [0 year] |
| MicroBioChips | 2010 .02 | Licensing-in of PlasmaScan antibody microarray products that speed-up identification of human plasma biomarkers from Biosystems | LICIN | [3 years] |
| MicroBioChips | 2009 .01 | Partnering marketing agreement (worldwide) with Abcam on custom antibody arrays | MKTG | [2 years] |
| MicroBioChips | 2008 .08 | Company move from Evreux to Paris with 10 times more space | ORGL | [2 years] |
| MicroBioChips | 2008 .07 | Set-up of UK subsidiary in London (led by Pascal Azabian) | ORGC | [2 years] |
| MicroBioChips | 2008 .06 | Certification : ISO 9001-2000 | INFO | [2 years] |
| MicroBioChips | 2007 .02 | Partnering distribution agreement with Vigene Tech, for the US market | MKTG | [0 year] |
| MicroBioChips | 2006 .05 | Company founded by Dr Vincent Saulot and Pascal Azabian, based in Evreux incubator | ORGF | [0 year] |
| MilleGen | 2010 .03 | Patent : granted on molecular evolution technology (MutaGen) by US office | LEGAL | [10 years] |
| MilleGen | 2008 .05 | Partnering research agreement with Accuro Biologics on reciprocal expertise | R&D | [8 years] |
| MilleGen | 2007 .03 | Partnering research agreement with LFB to develop new generation of therapeutic monoclonal antibodies | R&D | [7 years] |
| MilleGen | 2005 .09 | Partnering research agreement with Pierre Fabre, bio-informatics | R&D | [5 years] |
| MilleGen | 2001 .12 | Launch of MutalGen platform, a mutagenesis platform | MKTG | [2 years] |
| MilleGen | 1999 .10 | Company founded by 2 researchers, Hakim Kharrat and Khalil Bouayadi | ORGF | [0 year] |
| MitoProd | 2009 .03 | Partnering distribution agreement with Sigma-Aldrich for Customized Long RNA Oligonucleotides | MKTG | [4 years] |
| MitoProd | 2009 .01 | Patent : granted on new class of interfering RNA, called ciRNA (circularization of the active molecules) | LEGAL | [4 years] |
| MitoProd | 2008 .02 | Partnering distribution agreement with Eurobio Labs for European market | MKTG | [3 years] |
| MitoProd | 2006 .05 | 1st round-financing : 1.6 M€, by undisclosed investors | RFINA | [1 year] |
| MitoProd | 2005 .05 | Seed financing : 0.14 M€, by Aquitaine Création Innovation | SFIN | [0 year] |
| MitoProd | 2004 .09 | Company founded by Guillaume Plane (CEO), Nathalie Bonnefoy [CNRS], based on a technology discovered by Dr. Jean-Paul di Rago [CNRS, also co-founder] | ORGF | [0 year] |
| Murigenetics | 2008 .02 | Registration : orphan Drug designation by EMEA for Ascorbic Acid in Charcot disease | MKTG | [2 years] |
| Murigenetics | 2005 .08 | Company founded by Prof. Michel Fontès, Prof. Olivier Blain, Eric Halioua, Gwenhaël Le Boulay | ORGF | [0 year] |
| Mutabilis | 2009 .06 | Acquisition by start-up Pharma Omnium International (France), with company name maintained and Stéphane Huguet (Président POI), back as CEO | ACQ- | [7 years] |
| Mutabilis | 2007 .10 | Nomination : Stephan Fischer as CEO | ORGN | [6 years] |
| Mutabilis | 2005 .04 | Partnering research agreement with Chiron (today Novartis) to develop new generation of prophylactic vaccines | R&D | [3 years] |
| Mutabilis | 2004 .06 | 2nd round-financing : 8.0 M€, by Auriga Partners, Crédit Lyonnais P.E. (today Crédit Agricole P.E.), and previous shareholders | RFINB | [2 years] |
| Mutabilis | 2002 .07 | 1st round-financing : 2.0 M€, by Bioam, AXA P.E., Inserm-Transfert | RFINA | [0 year] |
| Mutabilis | 2002 .03 | Nomination : Stéphane Huguet [ex-Pharmacia, Phoenix, Fournier, Sandoz] as CEO | ORGN | [0 year] |
| Mutabilis | 2001 .08 | Company founded by Prof. Xavier Nassif, as a spin-off from Inserm | ORGF | [0 year] |
| Myosix | 2010 .02 | Patent : granted in EU, for MX’ technology, on new class of interfering RNA, called ciRNA (circularization of the active molecules) | LEGAL | [9 years] |
| Myosix | 2008 .09 | Certification : cell therapy laboratory as an authorized center to prepare Cell Therapy Product of clinical use, by AFSSAPS | INFO | [8 years] |
| Myosix | 2008 .04 | Partnering manufacturing agreement with Association Française contre les Myopathies (AFM, i.e. French Muscular Dystrophy Association) to support research on muscular pathologies and cell therapy | INDUS | [7 years] |
| Myosix | 2007 .04 | Production : cell therapy (beginning) in Saint Louis hospital (Paris) | INDUS | [6 years] |
| Myosix | 2002 .11 | Clinical trial (phase II) for cell therapy (beginning, first worldwide) | CLIN | [2 years] |
| Myosix | 2002 .07 | Partnering research agreement with Genzyme, including capital sharing (49%) | R&D | [1 year] |
| Myosix | 2000 .09 | Company founded by Dr Jean-Thomas Vilquin, Prof. Jean-Pierre Marolleau and Dr Scorsin, from a patent application on myoblast production technology filed by AP-HP, AFM (French Muscular Dystrophy Association) and INSERM | ORGF | [0 year] |
| NanoBiotix | 2009 .01 | Partnering research agreement with SonoDrugs consortium (Philips, Lipoid AG, and 13 universities within a 16 M€ budget) to develop new nanoparticulate drug carriers | R&D | [5 years] |
| NanoBiotix | 2008 .09 | Patent : granted on nanoXray anticancer platform (Europe) | LEGAL | [5 years] |
| NanoBiotix | 2006 .11 | 2nd round-financing : 7.0 M€, by Matignon Technologies, OTC Asset Management, and previous shareholders | RFINB | [3 years] |
| NanoBiotix | 2005 .03 | Company move from Labège (near Toulouse) to Paris | ORGL | [2 years] |
| NanoBiotix | 2004 .00 | 1st round-financing : 1.0 M€, by Buffalo University (USA) and founders | RFINA | [0 year] |
| NanoBiotix | 2003 .03 | Company founded by Laurent Levy (born 1971), Kader Boussaha , and 4 others | ORGF | [0 year] |
| Neorphys | 2009 .08 | 1st round-financing : 1.2 M€, by Soridec, CEA Valorisation, Fa Diese 2, Seillans and a number of independent business angels | RFINA | [3 years] |
| Neorphys | 2007 .03 | Seed financing : 0.3 M€, by Soridec and Inserm-Transfert Initiative (extended to 1.05 M€ in total, mid 2008, with CEA Valorisation as additional investor) | SFIN | [1 year] |
| Neorphys | 2006 .07 | Financing (no interest loan) : 0.25 M€, by OSEO Innovation and Crealia | DEBT | [0 year] |
| Neorphys | 2005 .09 | Company founded by Roger Lahana and Karine Larbouret | ORGF | [0 year] |
| Neovacs | 2010 .04 | Listing on Alternext : 10 M€ (IPO) | PBO | [17 years] |
| Neovacs | 2009 .12 | Clinical trial (phase II) for TNFa-kinoid, a therapeutic vaccine in rheumatoid arthritis patients failing TNFa monoclonal antibody therapy (beginning) | CLIN | [16 years] |
| Neovacs | 2008 .11 | Clinical trial (phase I-II) for TNFa-kinoid, a therapeutic vaccine for the treatment of TNFa dependent auto-immune diseases in South-Africa (beginning) | CLIN | [15 years] |
| Neovacs | 2008 .10 | Financing (no interest loan) : 5.4 M€ (and 2.5 M€ grant), by OSEO Innovation to support Tracker, a theranostics project concerning rheumatoid arthritis from Neovacs (leader) and Biomedical Diagnostics | DEBT | [15 years] |
| Neovacs | 2007 .07 | Round-financing : 13.0 M€, by Novartis and previous shareholders | RFIN | [14 years] |
| Neovacs | 2006 .06 | Licensing-out to Debiopharm with capital sharing | LICOUT | [13 years] |
| Neovacs | 2006 .06 | Nomination : Guy Fanneau de la Horie, as CEO | ORGN | [13 years] |
| Neovacs | 2004 .10 | Round-financing : 1.5 M€, by Truffle Ventures and 1.2 M€, by Anvar | RFIN | [11 years] |
| Neovacs | 2003 .07 | Nomination : Alain Huriez, as CEO (still, as Director, Truffle Venture) | ORGN | [10 years] |
| Neovacs | 2003 .06 | Round-financing : 3.5 M€, by Truffle Ventures and Europe Innovation (reaching 51% of capital) | RFIN | [10 years] |
| Neovacs | 1999 .00 | Licensing-out of HIV therapeutic vaccine to Aventis Pasteur | LICOUT | [5 years] |
| Neovacs | 1998 .00 | Nomination : Jean-François Bensahel, as CEO | ORGN | [4 years] |
| Neovacs | 1993 .04 | Company founded by Daniel Zagury (immunologist), as a spin-off from Pierre et Marie Curie Paris University | ORGF | [0 year] |
| Netris-Pharma | 2008 .06 | Company founded by Patrick Mehlen [Lyon University, CNRS, as head of scientific board], Agnès Bernet [Lyon University], and Rodolphe Pasquier-Desvignes, as CEO | ORGF | [0 year] |
| Neuronax | 2007 .08 | Licensing-out to Cells4Health (Holland) of first lead product NX peptide for clinical development | LICOUT | [4 years] |
| Neuronax | 2005 .06 | Patent : granted in USA on peptide | LEGAL | [2 years] |
| Neuronax | 2003 .03 | Company founded by Stéphane Gobron, Dr Fabrice Cailloux, Pierre-Yves Simonin [Pharm.D.], as a spin-off from Inserm | ORGF | [0 year] |
| NicOx | 2010 .05 | Registration : FDA advisory panel rejects naproxcinod (stock market off 45%, after announcement) | MKTG | [14 years] |
| NicOx | 2009 .12 | Public offering : 100 M€, with capital increase (closed) to FSI (€ 20 Millions), public funds (€ 10 Millions) and existing shareholders (€ 70 Millions) | PBO | [13 years] |
| NicOx | 2009 .09 | Registration : FDA submission of naproxcinod (then, EMEA, in December) | MKTG | [13 years] |
| NicOx | 2009 .08 | Acquisition (re-acquisition) of rights to PF-03187207 for glaucoma from Pfizer for 2 undisclosed milestones | ACQ+ | [13 years] |
| NicOx | 2009 .04 | Acquisition of Nitromed’s unlicensed patent estate covering nitric oxide-donating compounds for up to 6.0 M€ | ACQ+ | [13 years] |
| NicOx | 2008 .09 | Partnering secondary production agreement with Capsugel for the manufacture of Naproxcinod | INDUS | [12 years] |
| NicOx | 2008 .05 | Partnering primary production agreement with Archimica for the manufacture of Naproxcinod | INDUS | [12 years] |
| NicOx | 2007 .10 | Set-up of US subsidiary (headquarters) in New Jersey | ORGC | [11 years] |
| NicOx | 2007 .07 | Round-financing : 5.0 M€, by M.S.D., as milestone payment for licensing-in drug for hypertension | RFIN | [11 years] |
| NicOx | 2007 .02 | Public offering : 130 M€, with capital increase | PBO | [11 years] |
| NicOx | 2006 .05 | Clinical trial (phase III) for HCT3012 osteoarthritis drug (end of patient recrutment) | CLIN | [10 years] |
| NicOx | 2006 .04 | 3rd round-financing : 45.5 M€, for private international investors, with share increase and subsequent listing on Euronext | RFINC | [10 years] |
| NicOx | 2004 .10 | 2nd round-financing : 26.0 M€, for private international investors, with share increase and subsequent listing on Euronext | RFINB | [8 years] |
| NicOx | 2003 .02 | Financing : stock drop-down from 210 M€ to 36 M€ (max.: 450 M€ in June 2002), after disappointing results of clinical study | INFO | [7 years] |
| NicOx | 2004 .08 | Partnering research agreement with Pfizer | R&D | [8 years] |
| NicOx | 2001 .09 | Set-up of R&D center in northern Italy | ORGC | [5 years] |
| NicOx | 2001 .05 | Public offering : 59.0 M€ | PBO | [5 years] |
| NicOx | 1999 .11 | Listing on Paris Nouveau Marché : 27.4 M€ | PBO | [3 years] |
| NicOx | 1998 .06 | Company move from Paris to Sophia Antipolis (near Nice) | ORGL | [2 years] |
| NicOx | 1998 .03 | Partnering research agreement with Bayer (first of long series) | R&D | [2 years] |
| NicOx | 1997 .12 | 1st round-financing : 6.4 M€, led by Paribas P.I., Health Capital AB, with previous investors | RFINA | [1 year] |
| NicOx | 1996 .10 | Clinical trial (phase I) for anti-thrombotic (beginning) | CLIN | [0 year] |
| NicOx | 1996 .02 | Company founded by 3 pharmaceutical executives, Michele Garufi (CEO), Piero del Soldato, Elizabeth Robinson, from a primary legal entity in Eire in 1994, with financial support of Apax Partners, Sofinnova, European Medical Ventures | ORGF | [0 year] |
| Nokad | 2009 .10 | 1st round-financing : 1.6 M€, led by SHAM | RFINA | [5 years] |
| Nokad | 2008 .12 | Financing : grant of 0.9 M€, by ANR (Agence Nationale pour la Recherche) to support therapeutic vaccine projects in partnership with INSERM U790 Unit | DEBT | [4 years] |
| Nokad | 2007 .04 | Research : first fonctional KO mouse obtained, leading to a new function of erythropoietin receptor | R&D | [3 years] |
| Nokad | 2006 .04 | Set-up of US branch in Cambridge (MA) | ORGC | [2 years] |
| Nokad | 2005 .07 | Seed financing : undisclosed M€, by Cap Décisif and Genopole 1er Jour | SFIN | [1 year] |
| Nokad | 2004 .01 | Company founded by François Erard, Aymeric Dugray [left company in 2008], Abdelkader Yacchou, based on a project incubated by Amine Abina (before 2003) | ORGF | [0 year] |
| Nosopharm | 2009 .02 | Company founded by Philippe Villain-Guillot and Maxime Gualtieri | ORGF | [0 year] |
| Nova Decision | 2008 .10 | Partnering research collaboration with UCB using HitFast and SelectiveLead proprietary tools | R&D | [1 year] |
| Nova Decision | 2008 .05 | Partnering research collaboration with Ingenious Targeting laboratories (ITL) for a lead optimization program at ITL | R&D | [0 year] |
| Nova Decision | 2007 .09 | Company founded by Aziz Yasri, based on SARA v 1.0, a powerful QSAR/QSPR datamining platform for parallel and automatic descriptor selection and model building | ORGF | [0 year] |
| Novagali | 2010 .04 | Financing (no interest loan) : 9.4 M€, by OSEO, as the lead project company (with Stanipharm, Crossject, and CNRS) on retinopathy for Vitrena | DEBT | [9 years] |
| Novagali | 2009 .04 | Clinical trial (phase II) for with Cyclokat, a new formulation of Cyclosporine, in dry eye (completion) | CLIN | [8 years] |
| Novagali | 2009 .02 | Research : positive in vivo toxicity evaluation of BAK-free latanoprost formulation for glaucoma | R&D | [8 years] |
| Novagali | 2008 .12 | Registration : provisionally negative opinion from EMEA for lead compound Vekacia (non convincing results : dossier is withdrawn) | MKTG | [8 years] |
| Novagali | 2008 .09 | 4th round-financing : 15.0 M€, by previous shareholders | RFIND | [8 years] |
| Novagali | 2008 .04 | Launch of Cationorm on the French market, the first for the company | MKTG | [7 years] |
| Novagali | 2007 .03 | Clinical trial (phase III) for Vekacia in Vernal Keratoconjonctivitis (VKC) (completed, positive) | CLIN | [6 years] |
| Novagali | 2006 .04 | 3rd round-financing : 26.0 M€, with AGF P.E., Bernard Chauvin Group, and previous shareholders | RFINC | [5 years] |
| Novagali | 2006 .01 | Clinical trial (phase II) for Cyclosporin derivative (completed) | CLIN | [5 years] |
| Novagali | 2004 .12 | 2nd round-financing : 14.2 M€, with Edmond de Rothschild I.P., Siparex, and previous shareholders | RFINB | [4 years] |
| Novagali | 2004 .09 | Nomination : Jérôme Martinez as CEO | ORGN | [4 years] |
| Novagali | 2000 .09 | 1st round-financing : 3.8 M€, with CDC Enterprise Innovation, Auriga Ventures, 123 Multinova, FJCE (CDC), Crédit Agricole P.E. | RFINA | [0 year] |
| Novagali | 2000 .08 | Company founded by Prof. Simon Benita (Israel) and others | ORGF | [0 year] |
| NovoCIB | 2006 .11 | Nomination : Nicolas Godard as CEO, from a consultancy position in Genopole Évry | ORGN | [1 year] |
| NovoCIB | 2006 .05 | Company move from Grenoble to the former site of Merck-Lipha Santé, in Lyon city center | ORGL | [1 year] |
| NovoCIB | 2005 .05 | Company founded by Larissa Balakireva | ORGF | [0 year] |
| Novotec | 1997 .11 | Company founded by Sylviane Guerret, as a spin-off from Institut Pasteur, Lyon | ORGF | [0 year] |
| ObeTherapy | 2005 .06 | Partnering research agreement with Zambon (later acquired by Rottapharm), on low-molecular weight | R&D | [5 years] |
| Obe Therapy | 2002 .11 | Seed financing : 0.3 M€, by iXCore | SFIN | [2 years] |
| Obe Therapy | 2000 .01 | Company founded by Itzik Harosh, with public funds (Genopole 1er Jour, Anvar), amounting to 0.4 M€ | ORGF | [0 year] |
| Oligovax | 2001 .08 | Seed financing : 0.8 M€, by Global Millenium Fund | SFIN | [1 year] |
| Oligovax | 2000 .08 | Company founded by Paul van der Schueren, from AP-HP licensed patents | ORGF | [0 year] |
| Oncodesign | 2009 .08 | Financing (no interest loan) : 10.0 M€, by OSEO Innovation, for oncology biomarker program IMAkinib (with Guerbet and Ariana Pharmaceuticals) | DEBT | [14 years] |
| Oncodesign | 2008 .06 | Round-financing : 3.0 M€, by Banque de Vizille, Avenir Entreprise Gestion, in order to invest in USA and neurology | RFIN | [13 years] |
| Oncodesign | 2008 .03 | Launch of Pharm'Image platform, a medical imagery pole in Dijon, with local partners (completion planned for 2010) | MKTG | [13 years] |
| Oncodesign | 2007 .07 | Set-up of offices in Montréal, Canada | ORGC | [12 years] |
| Oncodesign | 1998 .07 | Seed financing : 0.75 M€, by Ideb, Banque Populaire Création | SFIN | [3 years] |
| Oncodesign | 1995 .01 | Company founded by Philippe Genne and Eric Solary (today Inserm), both scientists (Lab. Onco-hematology, Dijon University) | ORGF | [0 year] |
| Oroxcell | 2007 .06 | Launch of new technology cosmetic testing based on human skin, in cooperation with Episkin and Skinethic | MKTG | [2 years] |
| Oroxcell | 2007 .00 | Partnering contract agreement with Nosan (Japan) as their total agency in the medical product absorption | R&D | [2 years] |
| Oroxcell | 2004 .07 | Company founded by Jean Pachot | ORGF | [0 year] |
| Oxincell | 2006 .08 | Company founded by Dr Christelle Peyreigne and Dr Jean-Pierre Molès | ORGF | [0 year] |
| Palumed | 2009 .06 | Financing (no interest loan) : 9.0 M€, by OSEO Innovation, for the NOSOBIO program for prevention, diagnostics and treatment of hospital-acquired infections (with Serial Genetics, Genewave, Da Volterra, Institut Pasteur and Assistance Publique-Hôpitaux de Paris) | DEBT | [8 years] |
| Palumed | 2008 .05 | Patent : pending on 3rd generation Trioxaquines with Sanofi-Aventis | LEGAL | [7 years] |
| Palumed | 2006 .02 | Nomination : Bernard Meunier as CEO, replacing Claudine Meunier-Chesny (moving to Alliances Dir.) | ORGN | [5 years] |
| Palumed | 2002 .07 | 1st round-financing : undisclosed M€, by IRDI, SOCRI, FCJE (CDC), GSO Capital, followed by Viveris (2005) | RFINA | [1 year] |
| Palumed | 2000 .12 | Company founded by Bernard Meunier and Claudine Meunier-Chesny | ORGF | [0 year] |
| PharmaLeads | 2008 .11 | Licensing-out of analgesic PL37 to Debiopharm (Switzerland), beginning phase I, with € undisclosed Millions upfront payment | LICOUT | [7 years] |
| PharmaLeads | 2008 .10 | Clinical trial (phase I) for PL 37, own analgesic drug (beginning) | CLIN | [7 years] |
| PharmaLeads | 2006 .04 | Launch of new Fluofast high fluorescence library of peptide enzymes | MKTG | [5 years] |
| PharmaLeads | 2005 .01 | Management reshuffling : managers replacing scientific founders in operations | ORG | [4 years] |
| PharmaLeads | 2000 .12 | Company founded by a group of Inserm researchers led by Bernard Roques (Pharm.D., Ph.D. Physico-chemistry) and Marie-Claude Fournié-Zaluski (CEO, Ph.D. Chemistry) | ORGF | [0 year] |
| Pharmaxon | 2009 .11 | 1st round-financing : € 1.7 Million by SHAM (Société Hospitalière d’Assurances Mutuelles) and Primavéris | RFINA | [5 years] |
| Pharmaxon | 2008 .11 | Nomination : Glenn Stanley, as CEO, replacing Pascal Deschaseaux, moving as Gelarc Managing Director in Lyon (France) | ORGN | [4 years] |
| Pharmaxon | 2007 .05 | Licensing-in of PSA mimetic peptides from CNRS, 2 Universities and Schaffer-N (Denmark) | LICIN | [2 years] |
| Pharmaxon | 2006 .10 | Seed financing : 0.5 M€, by Inserm-Transfert Initiative, Esperante, Primavéris, Crédit Agricole AP Création | SFIN | [2 years] |
| Pharmaxon | 2004 .09 | Company founded by Pascal Deschaseaux [born 1960, M.D., MBA, ex-Pierre Fabre, Johnson & Johnson, Merck KGaA], Geneviève Rougon, Jean-Chrétien Norreel, as a spin-off from IBDM (Institut de Biologie et du Développement de Marseille-Luminy) | ORGF | [0 year] |
| Pharnext | 2009 .06 | Partnering R&D marketing agreement with Ipsen regarding innovative drug candidates intended for the treatment of Charcot Marie-Tooth disease, issued from the pleotherapy technology, against undisclosed amount of convertible bonds | R&D | [2 years] |
| Pharnext | 2007 .11 | Seed financing : 2.5 M€, by Truffle Capital | SFIN | [0 year] |
| Pharnext | 2007 .07 | Company founded by Daniel Cohen (CEO) and others | ORGF | [0 year] |
| PhenoPro | 2008 .08 | Partnering marketing agreement with Oncodesign, OncOptima, a new service offer for the characterization and validation of Genetically Engineered Mouse Model in cancer targeted therapies | MKTG | [0 year] |
| PhenoPro | 2007 .09 | Company founded by Nicolas Carboni (today, Managing Director of the Cluster Alsace-Biovalley), Catherine Schaeffer, and others, as a spin-off from MCI (Mouse Clinical Institute) | ORGF | [0 year] |
| Pherecydes Pharma | 2009 .09 | Nomination : Jérôme Gabard, replacing Thierry Raynaud (since beginning) | ORGN | [2 years] |
| Pherecydes Pharma | 2009 .08 | Financing (no interest loan) : 0.5 M€, by OSEO, for development and validation of 3 patented technologies, using its predictive integrative biology process (CADI) | DEBT | [2 years] |
| Pherecydes Pharma | 2009 .08 | 1st round-financing : 1.15 M€, by undisclosed investors | RFINA | [2 years] |
| Pherecydes Pharma | 2008 .10 | Company move from Paris to Biocitech in Romainville | ORGL | [1 year] |
| Pherecydes Pharma | 2006 .12 | Company founded by Manuel Géa, as a spin-off from BMSystems | ORGF | [0 year] |
| PolyIntell | 2008 .11 | Company move from Mont-Saint-Aignan (near Rouen) to Val-de-Reuil (Eure) with 700 m2 new laboratories | ORGL | [4 years] |
| PolyIntell | 2008 .09 | Seed financing : 0.8 M€, by 2 venture capitalists | SFIN | [4 years] |
| PolyIntell | 2004 .07 | Company founded by Kaynoush Naraghi, Sami Bayoudh (husband), and Karsten Haupt (Scientific advisor) | ORGF | [0 year] |
| PraXcell | 2007 .11 | Round-financing : 1.5 M€, in preparation | RFIN | [4 years] |
| PraXcell | 2006 .10 | Seed financing : 0.5 M€, by Galia Gestion and Fonds d'Amorçage Midi Pyrénées | SFIN | [2 years] |
| PraXcell | 2003 .11 | Company founded by Dr Patrice Richard, Dr Lin Zeng, Michel Eymeri | ORGF | [0 year] |
| Proteogenix | 2003 .01 | Company founded by Philippe Funfrock with Inserm researchers
(URL, also as www.proteogenix.fr : no link with the homonym US biotech) | ORGF | [0 year] |
| Protéus | 2007 .10 | Round-financing : undisclosed M€, as a share capital increase reserved for industrial partner PCAS, from 6% to 32% | RFIN | [9 years] |
| Protéus | 2005 .07 | Set-up of PSI, new division to trade protein services and production | ORGC | [7 years] |
| Protéus | 1999 .09 | Seed financing : 0.2 M€, by Axa P.I., Natexis Ventech | SFIN | [1 year] |
| Protéus | 1998 .01 | Company founded by Daniel Dupret (CEO, then President up to 2007) [co-founder, born 1956, Eng. Insa, ex-Transgene, Appligene], Jean-François Bloch, Jean-Marie Sonet [PCAS] and others | ORGF | [0 year] |
| Protexel | 2000 .08 | Company founded by Bernard Weill, Frédéric Batteux, as a spin-off of AP-HP (Cochin hospital), in Paris Biotech center | ORGF | [0 year] |
| PX’Therapeutics | 2009 .11 | Production : new additional biomanufacturing unit, dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells, in Grenoble (10th anniversary) | INDUS | [9 years] |
| PX’Therapeutics | 2008 .10 | Partnering manufacturing agreement with Alizé Pharma on a recombinant L-asparaginase | INDUS | [7 years] |
| PX’Therapeutics | 2008 .09 | Company name change from ProteineXpert to PX’Therapeutics, in order to highlight its focus on integrated biotherapeutics development and to avoid labeling confusions | INFO | [7 years] |
| PX’Therapeutics | 2008 .07 | Partnering co-commercialization agreement with Althea Technologies (San Diego, USA) | MKTG | [7 years] |
| PX’Therapeutics | 2007 .07 | Set-up of PX’Monoclonals subsidiary in Lyon, dedicated to the development of murine and humanized monoclonal antibodies for research and therapeutic purposes | ORGC | [6 years] |
| PX’Therapeutics | 2004 .09 | Set-up of PX’Pharma subsidiary to provide with cGMP clinical manufacturing services | ORGC | [3 years] |
| PX’Therapeutics | 2003 .11 | Round-financing : 1.3 M€, by undisclosed regional investors | RFIN | [3 years] |
| PX’Therapeutics | 2000 .11 | Company founded by Tristan Rousselle and Nicolas Mouz | ORGF | [0 year] |
| Quantum Genomics | 2009 .04 | Financing (no interest loan) : 0.7 M€, by OSEO Innovation, to finance the regulatory preclinical development of QGC 001 (the first drug to treat hypertension by targeting Aminopeptidase A) | DEBT | [3 years] |
| Quantum Genomics | 2008 .01 | Acquisition of Eurobiobiz (Clermont-Ferrand), specialized in high-value added project management | ACQ+ | [2 years] |
| Quantum Genomics | 2007 .06 | Partnering research agreement with Inserm and CNRS on their hypertension chemical entity, as QGC001 | R&D | [1 year] |
| Quantum Genomics | 2006 .07 | 1st round-financing : 3.0 M€, led by undisclosed investors | RFINA | [0 year] |
| Quantum Genomics | 2006 .06 | Company founded by US investors (New Jersey), with European HQ and management in Paris region | ORGF | [0 year] |
| Rhenovia Pharma | 2010 .04 | Partnering research collaborative project RHENEPI lead for 2.5 M€ over 3 years in order to develop a platform biosimulation of seizures (other partner Synapcell as CRO) | R&D | [2 years] |
| Rhenovia Pharma | 2009 .04 | Financing (grant) : 1.6 M€ (2.3 MUS$), by state R&D institution NIH (USA) shared by Biomedical Engineering, LAS and Rhenovia, over 4 years | RFIN | [1 year] |
| Rhenovia Pharma | 2007 .05 | Company founded by Serge Bischoff, Pr. Michel Baudry, Jan Kremers, and Michel Faupel | ORGF | [0 year] |
| ScarCell Therapeutics | 2007 .04 | Company founded by Antoine Lafont (M.D., APHP, Directeur de l’Unité Inserm U849), Bruno Gogly (M.D., APHP, Inserm U849), Bernard Coulomb (Ph.D., Inserm U849), as a spin-off of AP-HP (Cochin hospital), in Paris Biotech center | ORGF | [0 year] |
| Sepal Pharma | 2008 .04 | Nomination : Dr Frédéric Revah, as CEO | ORGN | [3 years] |
| Sepal Pharma | 2007 .09 | Management crisis : founder and CEO, Damien Salauze, on leave (for Institut Curie) | ORG | [3 years] |
| Sepal Pharma | 2005 .06 | Listing on LSE (London) : 3.8 M€ | PBO | [0 year] |
| Sepal Pharma | 2004 .08 | Company founded by Damien Salauze ([Pharm.D., MBA, ex-Auriga Partners, Rhône-Poulenc Rorer, Institut Pasteur], Christian Policard [ex-Sanofi], Max Herzberg and others, in Paris, with a subsidiary in Israel and a holding in London | ORGF | [0 year] |
| Serial Genetics | 2009 .07 | Partnering development agreement with Gendiag (Spain) for Thrombo InCode | R&D | [5 years] |
| Serial Genetics | 2009 .06 | Financing (no interest loan) : 9.0 M€, by OSEO Innovation, for the NOSOBIO program for prevention, diagnostics and treatment of hospital-acquired infections (with Oncodesign, Palumed, Da Volterra, Institut Pasteur and Assistance Publique-Hôpitaux de Paris) | DEBT | [5 years] |
| Serial Genetics | 2006 .08 | Seed financing : 0.4 M€, by undisclosed investors | SFIN | [2 years] |
| Serial Genetics | 2003 .10 | Company founded by Christophe Valat and François Nicolas | ORGF | [0 year] |
| Sisène Biotechnologies | 2008 .05 | Management major setback : Jean Plouët's death | ORG | [1 year] |
| Sisène Biotechnologies | 2008 .03 | Financial minority share (8.5%) acquired by Théa Laboratories (ophthalmology) | ACQ- | [0 year] |
| Sisène Biotechnologies | 2007 .05 | Company founded by Prof. Jean Marsac and Jean Plouët (co-discoverer of Vegf) | ORGF | [0 year] |
| Skuld-Tech | 2007 .02 | Partnering research agreement with Roche Diagnostics on rapid and accurate SAGE gene profiles | R&D | [7 years] |
| Skuld-Tech | 2006 .03 | Partnering research agreement with Genepep | R&D | [6 years] |
| Skuld-Tech | 1999 .06 | Company founded by Didier Ritter, Dr Philippe Piquemal, Philippe Outrebon, as a spin-off from Institut de Génétique Humaine (Montpellier) | ORGF | [0 year] |
| Synapcell | 2009 .03 | Seed financing : 0.7 M€ by Rhône-Alpes Création, Expansinvest, Grenoble Angels Participation, Viaduc8 | SFIN | [3 years] |
| Synapcell | 2005 .04 | Company founded by Corinne Roucard, Karine Bressand, Yann Roche, Antoine Depaulis (based on a trade name already active in 2002), based on a project stemmed in Université Joseph Fourier (Grenoble) | ORGF | [0 year] |
| Synprosis | 2008 .04 | Seed financing : 0.15 M€ by Nortia, Venice | SFIN | [4 years] |
| Synprosis | 2003 .06 | Company founded by Jean-Pierre Salles, in cooperation with Erwan Loret | ORGF | [0 year] |
| TcLand Expression | 2009 .10 | Clinical trial for validation study on K-RejX diagnostic blood test in identification of kidney transplant recipients at risk of chronic rejection (beginning) | CLIN | [7 years] |
| Tc Land Expression | 2009 .09 | Round financing : 1.0 M€ through Tepa law (plus 2.2 M€ as no interest loan from ANR for Tolestim development), to Tc Land Pharma | RFIN | [6 years] |
| Tc Land Expression | 2009 .04 | Financing (no interest loan) : 1.8 M€ from OSEO for innovation support | DEBT | [6 years] |
| Tc Land Expression | 2008 .08 | Licensing-in of a liver biomarker (worldwide rights) from Idibaps (Spain) | LICIN | [5 years] |
| Tc Land Expression | 2008 .01 | Set-up of CIMNA, an integrated immuno-monitoring service platform, located in Nantes | ORGC | [5 years] |
| Tc Land Expression | 2007 .12 | 1st round-financing : 8.2 M€, led by Auriga Partners | RFINA | [5 years] |
| Tc Land Expression | 2007 .12 | Company split into 2 autonomous units : TcLand Expression (previously TcLand) and TcLand Pharma, focused on the development of therapeutic molecules | ORG | [5 years] |
| Tc Land Expression | 2006 .00 | Nomination : Alain Huriez, as Chairman and CEO [ex-Neovacs CEO, 2003-2006] | ORGN | [3 years] |
| Tc Land Expression | 2006 .06 | Licensing-out to Debiopharm with capital sharing | LICOUT | [3 years] |
| Tc Land Expression | 2005 .06 | Seed financing : undisclosed M€, by Inserm-Transfert | SFIN | [2 years] |
| Tc Land Expression | 2002 .10 | Company founded by Marina Guillet, Alain Huriez, as a spin-off of Itert | ORGF | [0 year] |
| Theraclion | 2009 .02 | Financing (no interest loan) : 8.5 M€ (of which 3.5 M€ as grant), OSEO Innovation, as part of the TUCE strategic industrial innovation project on elastography-guided ultrasound therapy | DEBT | [4 years] |
| Theraclion | 2008 .00 | 1st round-financing follow-up) : 1.6 M€, by Truffle Venture | RFINA | [3 years] |
| Theraclion | 2007 .12 | Financing (no interest loan) : 1.3 M€ from OSEO Innovation (together with CE Mark approval) | DEBT | [3 years] |
| Theraclion | 2006 .03 | Clinical trial (phase II) for a non-invasive treatment of thyroid nodules (beginning) | CLIN | [1 year] |
| Theraclion | 2005 .04 | 1st round-financing : 3.5 M€, by Truffle Venture | RFINA | [0 year] |
| Theraclion | 2004 .08 | Company founded by François Lacoste (CEO), Gérard Hascoët [Promed, Sometec, IMMI, Technomed International], Jean Louis Hervy [Sapex, SMI], Annie Claude Benichou [M.D.], Guillaume Olivier Doré | ORGF | [0 year] |
| TheraVectys | 2008 .05 | Website under construction | INFO | [3 years] |
| TheraVectys | 2005 .05 | Company founded by Dr Pierre Charneau, as a spin-off from Institut Pasteur (Paris) | ORGF | [0 year] |
| Transgene | 2010 .03 | "Licensing-out (exclusive option) of TG4010, for the first-line treatment of non-small cell lung cancer (NSCLC) and other potential cancer indications, to Novartis (10 MUS$ non-refundable
option fee)" | LICOUT | [31 years] |
| Transgene | 2009 .12 | Designation of Fast Track Status by FDA for TG4010, a targeted immunotherapy for treatment of Non-Small Cell Lung Cancer | MKTG | [30 years] |
| Transgene | 2009 .05 | Launch of Platine, a joint immuno-monitoring platform, by 5 partners (Innate Pharma, Transgene, ImmunID, Inserm and Cancer Centre Léon-Bérard), based in Lyon | MKTG | [30 years] |
| Transgene | 2007 .06 | Public offering : 100.1 M€ | PBO | [28 years] |
| Transgene | 2007 .04 | Licensing-out of HPV vaccine lead to Roche | LICOUT | [28 years] |
| Transgene | 2006 .07 | Public offering : 14.3 M€, through exercise of warrants | PBO | [27 years] |
| Transgene | 2005 .06 | Public offering : 34.9 M€, with refocus on therapeutic vaccines | PBO | [26 years] |
| Transgene | 2004 .12 | Nomination : Philippe Archinard as CEO | ORGN | [25 years] |
| Transgene | 2002 .07 | Nomination : Jean-François Carmier as CEO [ex-Transgene V.P.] | ORGN | [23 years] |
| Transgene | 2001 .09 | Management restructuring : 30 heads employee reduction from 195 headcounts | ORGR | [22 years] |
| Transgene | 2001 .05 | Public offering : 63.0 M€ in depositary shares for Biomérieux-Pierre Fabre and AFM (French Muscular Dystrophy Association), with refocus on cancer treatments | PBO | [22 years] |
| Transgene | 2000 .11 | Nomination : Gilles Bélanger [ex-Biomérieux], as CEO | ORGN | [21 years] |
| Transgene | 1998 .03 | Listing on Paris Nouveau Marché and New York Nasdaq : 100 MUS$ (about 80 M€) | PBO | [19 years] |
| Transgene | 1995 .00 | Production : GMP manufacturing facility completed | INDUS | [15 years] |
| Transgene | 1992 .00 | Nomination : Bernard Gilly as CEO, with refocus on gene transfer technology | ORGN | [12 years] |
| Transgene | 1979 .00 | Company founded by Pierre Chambon (Ph.D., CNRS, Research Director at Pasteur Institute) and others | ORGF | [0 year] |
| Trophos | 2010 .03 | Clinical trial (phase III) for olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) (end recruitment) | CLIN | [11 years] |
| Trophos | 2010 .03 | Launch : new web site on Charcot disease for patients and health professionals at MitoTarget | MKTG | [11 years] |
| Trophos | 2009 .09 | Clinical trial planned, after first preclinical trial results on TRO40303, a novel TSPO ligand, significantly reducing myocardial infarct size | CLIN | [10 years] |
| Trophos | 2009 .03 | Financing (grant over 3 years) : 6.7 M€ by Association Française contre les Myopathies (AFM), for further clinical development of lead drug candidate olesoxime (TRO19622) as a treatment for Spinal Muscular Atrophy | RFIN | [10 years] |
| Trophos | 2008 .12 | Financing (no interest loan) : 6.0 M€, by the European Commission, to boost TRO19622 programs for ALS, within Trophos led consortium (Mitotarget) | DEBT | [9 years] |
| Trophos | 2008 .06 | Nomination : Damian Marron as CEO, replacing co-founder Antoine Béret [born 1944, ex-Immunotech] who retires | ORGN | [9 years] |
| Trophos | 2008 .02 | Financing (no interest loan) : 1.0 M€, by ANR, to support the project named IRIstop | DEBT | [9 years] |
| Trophos | 2007 .09 | 3rd round-financing : 8.5 M€, led by OTC Asset Management with CM-CIC Asset Management and previous shareholders | RFINC | [8 years] |
| Trophos | 2003 .04 | 2nd round-financing : 6.4 M€, led by Innoveris and previous shareholders | RFINB | [4 years] |
| Trophos | 1999 .01 | Company founded by Antoine Béret (CEO), Michel Deléage (venture capitalist), and 3 scientists (as consultants) | ORGF | [0 year] |
| TxCell | 2010 .04 | Clinical trial (phase II) for OvaSave in Crohn's Disease (positive preliminary results) | CLIN | [9 years] |
| TxCell | 2008 .03 | 2nd round-financing : 10.5 M€, by previous shareholders | RFINB | [6 years] |
| TxCell | 2006 .00 | Nomination : Frédéric Hammel, as CEO (H. Groux in supervisory board) | ORGN | [4 years] |
| TxCell | 2004 .10 | 1st round-financing : 10.5 M€, by Auriga Partners, AXA Private Equity, BioAm, CDC and SPEF Venture | RFINA | [3 years] |
| TxCell | 2004 .00 | Nomination : Philippe Ballero [ex-Yamanouchi, Proskelia], as CEO | ORGN | [2 years] |
| TxCell | 2001 .04 | Company founded by Dr Hervé Groux [CSO, ex-Inserm, CNRS] and Dr Françoise Cottrez, within Nice Archet Hospital, as a spin-off from Inserm | ORGF | [0 year] |
| UroGene | 2008 .08 | No website news update since November 2006 (net capital : - 3 M€ in December 2006, but legal capital increases in September 2007, August 2008 and August 2009) | INFO | [10 years] |
| UroGene | 2006 .01 | Seed financing : 1.5 M€, by historical investors | SFIN | [7 years] |
| UroGene | 2005 .01 | Divestiture of drug discovery platform (including Chrysalon) to Pierre Fabre | ACQ- | [6 years] |
| UroGene | 2004 .01 | Licensing-in of Besipirdine exclusive rights from Aventis | LICIN | [5 years] |
| UroGene | 2003 .03 | 2nd round-financing : 12.0 M€, led by Société Générale Asset Management (SGAM) | RFINB | [5 years] |
| UroGene | 2002 .07 | Acquisition of Chrysalon, a chemical company, spin-off from Aventis | ACQ+ | [4 years] |
| UroGene | 2000 .12 | Nomination : Christian Grenier [born 1950, Sup de Co Paris, MBA, ex-Rhône Poulenc], as CEO | ORGN | [2 years] |
| UroGene | 2000 .09 | 1st round-financing : 2.0 M€, by Société Générale A.M., business angels | RFINA | [2 years] |
| UroGene | 1998 .04 | Seed financing : 1.5 M€, by founders and public funding | SFIN | [0 year] |
| UroGene | 1998 .03 | Company founded by Dr Philippe Berthon [CEO, Ph.D. cancerology], Dr Olivier Cussenot [CSO, Ph.D., M.D. surgery, Prof. urology], with Pierre Teillac [born 1960] and others | ORGF | [0 year] |
| UROsphere | 2008 .10 | Research : development of new experimental models for stress or mixed urinary incontinence | R&D | [4 years] |
| UROsphere | 2007 .02 | Research : development of new experimental models for OverActive Bladder (OAB) and for Painful Bladder Syndrome (PBS) | R&D | [2 years] |
| UROsphere | 2004 .08 | Company founded by Philippe Lluel and Stefano Palea, as a spin-off from Sanofi-Synthelabo | ORGF | [0 year] |
| Urrma | 2008 .03 | 3rd round-financing : 9.0 M€, by undisclosed investors | RFINC | [6 years] |
| Urrma | 2005 .11 | Round-financing : undisclosed M€, by private investors | RFIN | [4 years] |
| Urrma | 2001 .06 | Company founded by Prof. Jean-Claude Chermann, Camille Haslin and Urrma Biopharma, based in Montreal, as a J.V. with a French subsidiary, which has since August 2004 become a French independent legal entity | ORGF | [0 year] |
| Vaxon Biotech | 2010 .05 | Clinical trial (phase II) for Vx-001 therapeutic vaccine (end), with 50% improvement of survival rate in SCLC patients (33) over standard treatment | CLIN | [6 years] |
| Vaxon Biotech | 2010 .02 | Registration : orphan Drug designation by FDA for Vx-001 in the treatment of NSCLC | MKTG | [6 years] |
| Vaxon Biotech | 2009 .00 | Nomination : François Vallet, as CEO, replacing Philippe Berthon | ORGN | [4 years] |
| Vaxon Biotech | 2007 .11 | Registration : orphan Drug designation by EMEA for Vx-001 in NSCL cancer | MKTG | [3 years] |
| Vaxon Biotech | 2004 .12 | Clinical trial (phase I) for Vx-001 (beginning, proof of principle) | CLIN | [0 year] |
| Vaxon Biotech | 2004 .06 | Company founded by Dr Kostas Kosmatopoulos, Inserm, with Philippe Berthon [Ph.D.] nominated as CEO | ORGF | [0 year] |
| Vectalys | 2007 .08 | Partnering research agreement with Pierre Fabre | R&D | [2 years] |
| Vectalys | 2005 .07 | Company founded by Pascale Bouillé | ORGF | [0 year] |
| VigiCell | 2008 .11 | Seed financing : 0.5 M€, by business angels and private investors (undisclosed) | SFIN | [9 years] |
| VigiCell | 2007 .06 | Partnering research agreement with L'Oréal | R&D | [8 years] |
| VigiCell | 2002 .05 | Nomination : Jean-Emmanuel Gilbert [Ph.D.], as CEO | ORGN | [2 years] |
| VigiCell | 1999 .06 | Company founded by Yolène Thomas [Ph.D., CNRS], Jean-Paul Oudinet [Ph.D., CNRS], Isaac Béhar [Ph.D.] and others | ORGF | [0 year] |
| Vivalis | 2010 .01 | Acquisition of Humalys, a private French biotech R&D company, based in Lyon, specialised in the generation of human monoclonal anti-bodies | ACQ+ | [10 years] |
| Vivalis | 2009 .01 | Partnering research agreement with Innate Pharma to produce IPH 4101 with EB66 for clinical trials (Oseo debt financing grant of 3.0 M€ for Vivalis) | R&D | [9 years] |
| Vivalis | 2008 .10 | Licensing-out of EB66 cell line to CSL to test for the development and manufacturing of a therapeutic protein candidate | LICOUT | [9 years] |
| Vivalis | 2007 .06 | Listing on Euronext : 29.0 M€ | PBO | [8 years] |
| Vivalis | 2005 .00 | Production : new manufacturing unit | INDUS | [5 years] |
| Vivalis | 2004 .11 | 2nd round-financing : 5.3 M€, by Grimaud Group, FCJE (CDC), Créagro, Pays de la Loire Développement, and banks, to finance the buiding of a manufacturing unit | RFINB | [5 years] |
| Vivalis | 2003 .00 | Partnering development with undisclosed company on Ebx cells | R&D | [3 years] |
| Vivalis | 1999 .06 | 1st round-financing : 4.6 M€, by Grimaud Group | RFINA | [0 year] |
| Vivalis | 1999 .04 | Company founded by Grimaud Group (Franck Grimaud), based on research know-how by Dr Bertrand Pain and Dr Jacques Samarut | ORGF | [0 year] |
| XenTech | 2008 .10 | 1st round-financing : 0.6 M€, by Aurinvest Capital 2 | RFINA | [2 years] |
| XenTech | 2006 .04 | Company founded by Jean-Gabriel Judde, Pascal Leuraud, Marie-France Poupon, Arnaud Beurdeley, as a spin-off from Institut Curie | ORGF | [0 year] |
| ZetaBiotech | 2008 .07 | Production : set-up of full manufacturing line | INDUS | [2 years] |
| Zeta Biotech | 2007 .06 | Listing on Euronext Paris : 1.5 M€ | PBO | [1 year] |
| Zeta Biotech | 2005 .10 | Company founded by Antony Guyader and Bruno Viola | ORGF | [0 year] |
| Adiatec ǂ | 2005 .12 | Company liquidation | INFO | [7 years] |
| Adiatec ǂ | 1998 .01 | Company founded by Joël Lesser | ORGF | [0 year] |
| Aptanomics ǂ | 2007 .07 | Financial complete burn-out and bankruptcy | INFO | [6 years] |
| Aptanomics ǂ | 2006 .11 | Divestiture of some R&D assets to Imaxio (UK) | LICOUT | [5 years] |
| Aptanomics ǂ | 2005 .06 | Partnering research agreement with Boehringer-Ingelheim in aptamer-based target validation | R&D | [4 years] |
| Aptanomics ǂ | 2003 .05 | Nomination : Michael Courtney [ex-Transgene], as CEO | ORGN | [2 years] |
| Aptanomics ǂ | 2002 .11 | 1st round-financing : 7 M€, by AGF P.E., CDC Ixis, Ventech | RFINA | [1 year] |
| Aptanomics ǂ | 2001 .03 | Company founded by John Hawken, Pierre Colas [Inserm, CSO], as a spin-off from Normale Sup (Lyon), based on patents from Massachusetts General Hospital | ORGF | [0 year] |
| Bionexis Pharmaceuticals ǂ | 2004 .12 | Company liquidation | INFO | [2 years] |
| Bionexis Pharmaceuticals ǂ | 2004 .02 | 1st round-financing : 6 M€, led by Edmond de Rotschild I.P., with Bioam, Sophia Euro lab, FCJE (CDC), CEA | RFINA | [2 years] |
| Bionexis Pharmaceuticals ǂ | 2004 .02 | Company move from Saclay (CEA) to Paris (Biotech) | RELOC | [2 years] |
| Bionexis Pharmaceuticals ǂ | 2002 .02 | Company founded by Françoise Russo-Marie and Alain Samson | ORGF | [0 year] |
| Bionisis ǂ | 2008 .03 | Company liquidation | INFO | [8 years] |
| Bionisis ǂ | 2002 .09 | 2nd round-financing : 2.5 M€ | RFINB | [2 years] |
| Bionisis ǂ | 1999 .10 | Company founded by unknown entrepreneurs | ORGF | [0 year] |
| Carex ǂ | 2006 .05 | Acquisition by 7TM Pharma (Denmark) | ACQ- | [5 years] |
| Carex ǂ | 2004 .03 | 2nd round-financing : 25 M€, by Crédit Lyonnais P.E., Global Life Science Ventures, BioMedinvest, HBM, and previous shareholders | RFINB | [3 years] |
| Carex ǂ | 2002 .07 | Nomination : Geoffrey Race, as CEO | | [1 year] |
| Carex ǂ | 2002 .04 | 1st round-financing : 6 M€, led by Sofinnova Partners, GIMV and Mara Ventures | RFINA | [1 year] |
| Carex ǂ | 2001 .11 | Company founded by Johan Auwerx, Pierre Chambon, Samir S. Deeb, Hana Koutnikova, Jürgen M.Lehmann, based on research from Institut de Génétique et de Biologie Moléculaire et Cellulaire, by Pierre Chambon (President of the board) | ORGF | [0 year] |
| Celogos ǂ | 2006 .01 | Acquisition by HRA Pharma of majority share, with Celogos maintained as a French subsidiary and Christian Pinset as CSO | ACQ- | [4 years] |
| Celogos ǂ | 2005 .11 | Partnering research agreement, HRA Pharma, for pharmaceutical development process of future lead compounds | R&D | [4 years] |
| Celogos ǂ | 2001 .08 | Company founded by Christian Pinset, cell therapy expert and Didier Montarras (from Institut Pasteur, in Paris) | ORGF | [0 year] |
| Cellpep ǂ | 2006 .03 | Acquisition by Procyon (Canada), for 39 MUS$, to form a new legal entity, Ambrilia Biopharma (www.ambrilia.com) | ACQ- | [8 years] |
| Cellpep ǂ | 2003 .03 | Round-financing : 3.8 M€, by Turenne Capital Partenaires, OTC Asset Management, H2i Management, Synergènes | RFIN | [5 years] |
| Cellpep ǂ | 1998 .00 | Company founded by Bonabes de Rougé, Michel Mollard and others | ORGF | [0 year] |
| Diatos ǂ | 2009 .05 | Company bankruptcy (in need of € 10 Million re-financing), then liquidation | INFO | [10 years] |
| Diatos ǂ | 2008 .12 | Licensing-out of DTS-108, a pro-drug of irinotecan to Drais (with co-development) | LICOUT | [9 years] |
| Diatos ǂ | 2008 .08 | Clinical trial (phase IIa) for DTS-201, a peptidic prodrug of doxorubicin (beginning) | CLIN | [9 years] |
| Diatos ǂ | 2007 .07 | 4th round-financing : 9.4 M€, by Credit Agricole P.E. and previous shareholders | RFIND | [8 years] |
| Diatos ǂ | 2006 .07 | Listing : failure of IPO introduction on Alternext, cancelled due to unfavorable market conditions | PBO | [7 years] |
| Diatos ǂ | 2006 .05 | Licensing-in of specialty cancer product from Gilead | LICIN | [7 years] |
| Diatos ǂ | 2005 .04 | Set-up of US subsidiary in California, USA (Business) | ORGC | [6 years] |
| Diatos ǂ | 2004 .03 | Set-up of subsidiary in Leuven, Belgium (R&D) | ORGC | [5 years] |
| Diatos ǂ | 2004 .02 | 3rd round-financing : 7.0 M€, by Innoven and BFF (Biotech Fund Flanders) | RFINC | [5 years] |
| Diatos ǂ | 2003 .05 | 2nd round-financing : 9.0 M€, by NIF and Crédit Lyonnais P.E. (today Crédit Agricole P.E.) | RFINB | [4 years] |
| Diatos ǂ | 2003 .04 | Licensing-out of cancer improved-delivery drug development to Medarex | LICOUT | [4 years] |
| Diatos ǂ | 2000 .10 | 1st round-financing : 15.5 M€, led by GIMV and InterWest Partners, with Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners | RFINA | [1 year] |
| Diatos ǂ | 1999 .05 | Seed financing : 1.5 M€, by Sofinnova Partners (subsequently John Tchélingérian joins the company as business developper) | SFIN | [0 year] |
| Diatos ǂ | 1999 .02 | Company founded by Prof. Stratis Avraméas, Dr Thérèse Ternynck, as a spin-off from Institut Pasteur | ORGF | [0 year] |
| Drugabuse Sciences ǂ | 2008 .05 | Company liquidation : legal dissolution | INFO | [10 years] |
| Drugabuse Sciences ǂ | 2007 .01 | Divestiture of assets (product portfolio, including naltrexone) to Elbion (Belgium) for undisclosed terms | ACQ- | [9 years] |
| Drugabuse Sciences ǂ | 2006 .06 | Listing on Alternext processed : 20 M€ expected (failed) | PBO | [8 years] |
| Drugabuse Sciences ǂ | 2004 .01 | Acquisition of mother US company by French subsidiary, with new CEO (Robert Floch) and 4.0 M€ convertible loan by CDC Ixis | ACQ+ | [6 years] |
| Drugabuse Sciences ǂ | 2001 .04 | Round-financing : 27.0 M€, by Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management | RFIN | [3 years] |
| Drugabuse Sciences ǂ | 1999 .10 | Round-financing : 21.0 M€, by 3i, ABN Amro, Auriga, CDC Innovation, Financière de Brienne, Nomura, Parnib, Partech, Rothschild Asset Management, Société Générale A.M. | RFIN | [1 year] |
| Drugabuse Sciences ǂ | 1997 .12 | Company founded by Philippe Pouletty (today Truffle Ventures), with name also shortened as DAS | ORGF | [0 year] |
| EndoCells ǂ | 2008 .05 | Acquisition by Esperante Ventures (Holland) | ACQ- | [3 years] |
| EndoCells ǂ | 2004 .08 | Company founded by Prof. Paul Czernichow [M.D. pediatry], Raphaël Scharfmann [Inserm] | ORGF | [0 year] |
| Fovea Pharmaceuticals ǂ | 2009 .10 | Acquisition by Sanofi Aventis (France), for 370 M€ | ACQ- | [4 years] |
| Fovea Pharmaceuticals ǂ | 2009 .05 | Clinical trial (proof-of-concept, positive) for Prednisporin (FOV1101) in patients with persistent allergic conjunctivitis | CLIN | [4 years] |
| Fovea Pharmaceuticals ǂ | 2009 .02 | Licensing-in of European rights of an ocular formulation of DX-88 for the treatment of retinal diseases from Dyax | LICIN | [3 years] |
| Fovea Pharmaceuticals ǂ | 2007 .12 | 2nd round-financing : 30.0 M€, by previous shareholders | RFINB | [2 years] |
| Fovea Pharmaceuticals ǂ | 2007 .11 | Partnering research agreement with Genzyme | R&D | [2 years] |
| Fovea Pharmaceuticals ǂ | 2005 .11 | 1st round-financing : 20.5 M€, by Sofinnova Partners, CAPE, Abingsworth Management, The Wellcome Trust, GIMV | RFINA | [0 year] |
| Fovea Pharmaceuticals ǂ | 2005 .05 | Company founded by Bernard Gilly, Pierre Bélichard, Prof. José-Alain Sahel (professor, Ophthalmology), based on platform from INSERM research unit 592 | ORGF | [0 year] |
| Génopoïetic ǂ | 2008 .11 | Nomination : François R. Martelet (Avax CEO since 2007) as President, and Isabelle Fourthin as Managing Director | ORGN | [14 years] |
| Génopoïetic ǂ | 2000 .08 | Acquisition by Avax Technologies, Philadelphia (USA) | ACQ- | [6 years] |
| Génopoïetic ǂ | 1994 .11 | Round-financing : undisclosed M€, by Rhône-Poulenc Rorer (France), against a minority share to support gene therapy trials | RFIN | [0 year] |
| Génopoïetic ǂ | 1993 .12 | Company founded by David Klatzmann and Jean-Loup Salzmann with the support of UPMC (Université Pierre et Marie Curie), with Charles Salzmann as CEO | ORGF | [0 year] |
| Genset ǂ | 2002 .06 | Acquisition by Serono (Switzerland) [today Merck-Serono] | ACQ- | [13 years] |
| Genset ǂ | 1996 .06 | Listing on Nasdaq : 100 MUS$ (about 80 M€) | PBO | [7 years] |
| Genset ǂ | 1989 .00 | Company founded by Marc Vasseur (a leading French scientist), Pascal Brandys (CEO, venture capitalist) | ORGF | [0 year] |
| Hemosystem ǂ | 2006 .10 | Company liquidation | INFO | [7 years] |
| Hemosystem ǂ | 2004 .09 | Round-financing : 3.0 M€, by FCJE (CDC), and previous shareholders | RFIN | [5 years] |
| Hemosystem ǂ | 1999 .05 | Company founded by Jean-Pierre Hermet (CEO) | ORGF | [0 year] |
| IDM Pharma ǂ | 2009 .05 | Acquisition by Takeda, for US$ 75 Million | ACQ- | [22 years] |
| IDM Pharma ǂ | 2008 .02 | Partnering research agreement ended with Sanofi-Aventis, after disappointing results on Junovan | R&D | [21 years] |
| IDM Pharma ǂ | 2007 .06 | Nomination : Timothy Walbert, new CEO and Chairman, with resignation by founder Jean-Loup Romet-Lemonne | ORGN | [20 years] |
| IDM Pharma ǂ | 2005 .03 | Acquisition by Epimune, as a merger with name change from IDM to IDM-Pharma | ACQ- | [18 years] |
| IDM Pharma ǂ | 2002 .12 | Round-financing : 20.0 M€, by Sanofi-Synthelabo (exclusive, shareholding : 11%) | RFIN | [15 years] |
| IDM Pharma ǂ | 2002 .01 | Partnering research agreement with Sanofi-Synthelabo | R&D | [15 years] |
| IDM Pharma ǂ | 2000 .11 | Round-financing: 48.9 M€ | RFIN | [13 years] |
| IDM Pharma ǂ | 1993 .12 | Company founded by Jean-Loup Romet-Lemonne (as Immuno-Designed Molecules, IDM) | ORGF | [6 years] |
| Ivagen ǂ | 2008 .07 | Company liquidation | INFO | [6 years] |
| Ivagen ǂ | 2007 .04 | Round-financing : undisclosed M€, by Matignon I.G., OTC Asset Management (after receivership in 2004) | RFIN | [5 years] |
| Ivagen ǂ | 2002 .02 | Company founded by Jean-Claude Aziza (unexpectedly deceased in 2006), Gilbert Skorski | ORGF | [0 year] |
| Meristem Therapeutics ǂ | 2008 .08 | Company liquidation | INFO | [10 years] |
| Meristem Therapeutics ǂ | 2007 .10 | Court : applications on appeal for GMO corn testing, rejected by tribunal | LEGAL | [9 years] |
| Meristem Therapeutics ǂ | 2004 .02 | Nomination : Jean-Paul Rohmer, chairman of Supervisory Board | ORGN | [5 years] |
| Meristem Therapeutics ǂ | 2002 .06 | 4th round-financing : 21.5 M€, by AGF P.E., Antin Innovation, CPR P.E., Innoven, Edmond de Rotschild I.P., Odyssée Ventures, Pechel Industrie, SPEF, and previous shareholders | RFIND | [4 years] |
| Meristem Therapeutics ǂ | 2001 .07 | Listing : failure of IPO introduction due to unfavorable financial environment for 54 M€ expected | PBO | [3 years] |
| Meristem Therapeutics ǂ | 2000 .11 | Acquisition of Sedaherb, phyto-subcontractor to pharmaceutical industry, for around 1 year turnover, 3.5 M€ | ACQ+ | [2 years] |
| Meristem Therapeutics ǂ | 2000 .06 | 3rd round-financing : 10.0 M€, by BNP, Tethys, 3i, Sofipar, Sofimac | RFINC | [2 years] |
| Meristem Therapeutics ǂ | 1999 .02 | 2nd round-financing : 18.3 M€, by Banexi Ventures 2, Banexi, 3i, Sofimac (Société de Financement du Massif Central), Sofipar (groupe Crédit Agricole) and capital disposal by Limagrain to the financial investors | RFINB | [0 year] |
| Meristem Therapeutics ǂ | 1998 .05 | 1st round-financing : 10.0 M€, by Limagrain | RFINA | [0 year] |
| Meristem Therapeutics ǂ | 1998 .04 | Company founded by Limagrain (Agro-food cooperative company, the number one seed producer in Europe), based on an innovative technology (Molecular Pharming) developped since 1992 | ORGF | [0 year] |
| Nautilus Biotech ǂ | 2008 .11 | Company liquidation | INFO | [8 years] |
| Nautilus Biotech ǂ | 2007 .04 | Clinical trial (phase I) for Belerofon in USA (beginning) | CLIN | [7 years] |
| Nautilus Biotech ǂ | 2007 .04 | 4th round-financing : 8.4 M€, by Pre-IPO Invest, Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap. | RFIND | [7 years] |
| Nautilus Biotech ǂ | 2007 .02 | Partnering research agreement with Wyeth on hemophilia therapies | R&D | [7 years] |
| Nautilus Biotech ǂ | 2005 .02 | 3rd round-financing : 7.25 M€, by Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap. | RFINC | [5 years] |
| Nautilus Biotech ǂ | 2005 .02 | Nomination : Philip Parkinson as CFO (then CEO, in 2007) | ORGN | [5 years] |
| Nautilus Biotech ǂ | 2003 .10 | Nomination : Reinhard Koenig [M.D.], as Vice President Clinical & Regulatory Affairs of Nautilus Biotech USA | ORGN | [3 years] |
| Nautilus Biotech ǂ | 2000 .08 | 1st round-financing : 0.9 M€, by undisclosed investors | RFINA | [0 year] |
| Nautilus Biotech ǂ | 2000 .01 | Company founded by Dr Manuel Vega (CEO) et Paul Martin | ORGF | [0 year] |
| Neuro3D ǂ | 2007 .03 | Liquidation and divestiture of R&D assets to Evotec (Germany) | INFO | [6 years] |
| Neuro3D ǂ | 2005 .05 | Clinical trial (phase III) for key lead compound, ocaperidone, licensed to J&J (beginning) | CLIN | [4 years] |
| Neuro3D ǂ | 2004 .12 | 4th round-financing : 31.5 M€, by previous shareholders | RFIND | [4 years] |
| Neuro3D ǂ | 2003 .09 | 3rd round-financing : 10.0 M€, by previous shareholders | RFINC | [3 years] |
| Neuro3D ǂ | 2003 .05 | Acquisition of Neurofit (France), a biotech CRO | ACQ+ | [2 years] |
| Neuro3D ǂ | 2002 .09 | 2nd round-financing : 20.0 M€, led by HealthCap, with Techno Venture Management and previous shareholders | RFINB | [2 years] |
| Neuro3D ǂ | 2002 .03 | Licensing-out of Ocaperidone to Janssen (J&J) | LICOUT | [1 year] |
| Neuro3D ǂ | 2000 .11 | 1st round-financing : 7.6 M€, by founder V.C., Apax Partners | RFINA | [0 year] |
| Neuro3D ǂ | 2000 .09 | Company founded by Sofinnova, Charles Woler (CEO), Jean-Jacques Bourguignon, Jean-Paul Macher | ORGF | [0 year] |
| Neurotech ǂ | 2006 .06 | Company move from Paris to Delaware (USA), as the legal domicile, with change in nationality and website as www.neurotechusa.com | ORGL | [8 years] |
| Neurotech ǂ | 2003 .11 | 4th round-financing : 12.0 M€, led by Apax Partners and Merlin Biosciences, with previous shareholders (3i Plc, GIMV, West LB, Atlas Venture and Ergo Equity) | RFIND | [5 years] |
| Neurotech ǂ | 2002 .01 | Licensing-in agreement of CNTF with Amgen in all ophthalmology indications | LICIN | [4 years] |
| Neurotech ǂ | 2001 .05 | 3rd round-financing : 35.0 M€, led by Apax Partners and Merlin Biosciences with Westdeutsche Landesbank Girozentrale, ABN Amro, Rotschild, AGF Innovation, and previous shareholders (3I Plc, GIMV, Atlas Venture, CDC Innovation, Sofinnova, Sudinnova, Banque de Vizille, IMH) | RFINC | [3 years] |
| Neurotech ǂ | 2000 .00 | Set-up of US subsidiary in Lincoln | ORGC | [1 year] |
| Neurotech ǂ | 1998 .10 | Company founded by unknown entrepreneurs | ORGF | [0 year] |
| Novexel ǂ | 2010 .03 | Company move from Romainville to USA (premises down, 40 staffs out) | ORGL | [5 years] |
| Novexel | 2009 .12 | Acquisition by AstraZeneca (UK) for at least US$ 430 Millions | ACQ- | [5 years] |
| Novexel ǂ | 2008 .11 | Clinical trial (phase II) for combined NXL104/ceftazidime in Hospital Patients with complicated Urinary Tract Infections (beginning) | CLIN | [4 years] |
| Novexel ǂ | 2008 .04 | Licensing-out of NXL 104, a beta-lactamase inhibitor, to Forest (USA), with € 75 Millions upfront payment | LICOUT | [3 years] |
| Novexel ǂ | 2008 .01 | Set-up of US subsidiary in Pennsylvania | ORGC | [3 years] |
| Novexel ǂ | 2007 .01 | 2nd round-financing : 50.0 M€, led by Edmond de Rothschild I.P., with Goldman Sachs, NeoMed, NIF SMBC, and previous shareholders | RFINB | [2 years] |
| Novexel ǂ | 2006 .12 | Licensing-in of Aminocandin from Indevus Biotech (USA) | LICIN | [2 years] |
| Novexel ǂ | 2005 .10 | Clinical trial (phase I) for NXL 103 (beginning) | CLIN | [1 year] |
| Novexel ǂ | 2004 .12 | 1st round-financing : 40.0 M€, led by Atlas Venture, with Sofinnova, 3i, Abingworth, Novo | RFINA | [0 year] |
| Novexel ǂ | 2004 .12 | Company founded by Dominique Le Beller and others, as a spin-off from Sanofi-Aventis [ex-Aventis Pharma] | ORGF | [0 year] |
| Opi ǂ | 2007 .03 | Acquisition by Eusa Pharma (USA) | ACQ- | [8 years] |
| Opi ǂ | 2004 .04 | 3rd round-financing : 6.4 M€, led by SPEF and Siparex, with previous shareholders | RFINC | [5 years] |
| Opi ǂ | 2003 .05 | Acquisition of Diaclone (France) | ACQ+ | [4 years] |
| Opi ǂ | 2003 .00 | 2nd round-financing : 4.5 M€, by Sofimac, CDC-PME, Innoveris | RFINB | [3 years] |
| Opi ǂ | 2001 .00 | 1st round-financing : 1.1 M€, by previous shareholders | RFINA | [1 year] |
| Opi ǂ | 1999 .01 | Company founded by Gilles Alberici [ex-Imtix, CEO], as 'Orphan Pharma International' | ORGF | [0 year] |
| ShigaMediX ǂ | 2009 .06 | Company liquidation | INFO | [3 years] |
| ShigaMediX ǂ | 2007 .11 | Partnering research agreement with GSK Biologicals on vaccines | R&D | [2 years] |
| ShigaMediX ǂ | 2006 .10 | Nomination : Jean-Marie Zacharie, as President and CEO | ORGN | [1 year] |
| ShigaMediX ǂ | 2005 .08 | Company founded by Ludger Johannes [Ph.D.] from Curie Institute/CNRS and Eric Tartour [M.D./Ph.D.] | ORGF | [0 year] |
| Synt:em ǂ | 2006 .01 | Acquisition by CLL Pharma (France), a development stage drug delivery pharmaceutical company, in shares | ACQ- | [11 years] |
| Synt:em ǂ | 2004 .11 | Acquisition (failed) by Sonus (USA), for 30 MUS$ in shares | ACQ- | [9 years] |
| Synt:em ǂ | 1995 .00 | Company founded by Michel Kaczorek (CEO), Caroline Roussel | ORGF | [0 year] |
| Theraptosis ǂ | 2008 .12 | Company liquidation (board of directors based decision) | INFO | [7 years] |
| Theraptosis ǂ | 2007 .09 | Nomination : Olivier Chesnoy [M.D.] as CEO | ORGN | [6 years] |
| Theraptosis ǂ | 2007 .02 | Company move to the Biocitech Park at Romainville (Paris North) | ORGL | [5 years] |
| Theraptosis ǂ | 2006 .12 | 2nd round-financing : 8.4 M€, led by Auriga Partners, with Blue Medical, Seventure, Edmond de Rothschild (EdRIP), CDC entreprises (FCJE) | RFINB | [5 years] |
| Theraptosis ǂ | 2006 .10 | Registration : orphan drug designation by EMEA for a treatment of neonatal brain damage | MKTG | [5 years] |
| Theraptosis ǂ | 2002 .07 | 1st round-financing : 2.5 M€, by undisclosed investors | RFINA | [1 year] |
| Theraptosis ǂ | 2001 .03 | Company founded by Léna Edelman and Etienne Jacotot, as a spin-off from Institut Pasteur, Paris | ORGF | [0 year] |
| Transat ǂ | 2008 .03 | Company liquidation | INFO | [5 years] |
| Transat ǂ | 2006 .01 | Seed financing : 1.2 M€, by Evolem, Oseo, Région Rhône-Alpes, and Philippe Desmarescaux (born 1938), as business angel | SFIN | [3 years] |
| Transat ǂ | 2002 .12 | Company founded by Sophie Chappuis and Marc Billaud (CNRS) | ORGF | [0 year] |
| Valigen ǂ | 2002 .05 | Company liquidation | INFO | [5 years] |
| Valigen ǂ | 2001 .05 | Nomination : Cécile Tharaud, as CEO | ORGN | [4 years] |
| Valigen ǂ | 2000 .02 | Acquisition of Kimeragen (USA), by merger | ACQ+ | [3 years] |
| Valigen ǂ | 1997 .02 | Acquisition of Infogen (Germany) | ACQ+ | [0 year] |
| Valigen ǂ | 1996 .12 | Company founded by Jean-Louis Pourny, from the merger of Valigène (France) and Kimeragen (USA) | ORGF | [0 year] |
